WO1998042670A1 - Novel pyridine derivatives and pharmaceutical compositions containing them - Google Patents
Novel pyridine derivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- WO1998042670A1 WO1998042670A1 PCT/SE1998/000505 SE9800505W WO9842670A1 WO 1998042670 A1 WO1998042670 A1 WO 1998042670A1 SE 9800505 W SE9800505 W SE 9800505W WO 9842670 A1 WO9842670 A1 WO 9842670A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridin
- methyl
- biphenyl
- hydroxy
- butoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 265
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 112
- 239000002253 acid Substances 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- -1 nitro, cyano, pyridyl Chemical group 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
- 206010039083 rhinitis Diseases 0.000 claims description 14
- 150000003839 salts Chemical group 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 11
- 239000012453 solvate Chemical group 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 239000004305 biphenyl Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- SYHJILPZUNKNHQ-UHFFFAOYSA-N 3-phenylbenzonitrile Chemical compound N#CC1=CC=CC(C=2C=CC=CC=2)=C1 SYHJILPZUNKNHQ-UHFFFAOYSA-N 0.000 claims description 6
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- XZUSIPDBUGNOCM-HTAPYJJXSA-N (3r,4s)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-HTAPYJJXSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- XZUSIPDBUGNOCM-JTSKRJEESA-N (3s,4s)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-JTSKRJEESA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- XZUSIPDBUGNOCM-VGOFRKELSA-N (3r,4r)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-VGOFRKELSA-N 0.000 claims description 3
- DDGJRSWNVRZGOE-OYHNWAKOSA-N (3r,4s)-4-[4-(3,4-dichlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(Cl)C(Cl)=C1 DDGJRSWNVRZGOE-OYHNWAKOSA-N 0.000 claims description 3
- NXMUFBHNKCDEAO-OYHNWAKOSA-N (3r,4s)-4-[4-(4-amino-2-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(N)C=C1Cl NXMUFBHNKCDEAO-OYHNWAKOSA-N 0.000 claims description 3
- ZCXVNJFAOLYGCZ-KSFYIVLOSA-N (3r,4s)-4-[4-(4-fluorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C=C1 ZCXVNJFAOLYGCZ-KSFYIVLOSA-N 0.000 claims description 3
- FXPVJVDIFNPJNT-RXFWQSSRSA-N (3r,4s)-4-[4-[3-[2-(dimethylamino)ethyl]phenyl]phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(CCN(C)C)=C1 FXPVJVDIFNPJNT-RXFWQSSRSA-N 0.000 claims description 3
- XZUSIPDBUGNOCM-VGSWGCGISA-N (3s,4r)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-VGSWGCGISA-N 0.000 claims description 3
- XMQYUZAOZUVRSG-GAJHUEQPSA-N 2,2,2-trifluoro-n-[3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-n-methylacetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(N(C)C(=O)C(F)(F)F)=C1 XMQYUZAOZUVRSG-GAJHUEQPSA-N 0.000 claims description 3
- DFFYDHKIRKXHRU-UQBPGWFLSA-N 2-[3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-n,n-dimethylacetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(CC(=O)N(C)C)=C1 DFFYDHKIRKXHRU-UQBPGWFLSA-N 0.000 claims description 3
- YOXBHJRLXHBBFP-YCRPNKLZSA-N 2-fluoro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(S(N)(=O)=O)C(F)=C1 YOXBHJRLXHBBFP-YCRPNKLZSA-N 0.000 claims description 3
- MRSJYLSUXBINPT-OYHNWAKOSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC(C(F)(F)F)=CC(S(N)(=O)=O)=C1 MRSJYLSUXBINPT-OYHNWAKOSA-N 0.000 claims description 3
- XVBDWBTYOLKWEW-RXFWQSSRSA-N 3-[6-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxynaphthalen-2-yl]-1-morpholin-4-ylpropan-1-one Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1C=C2)=CC=C1C=C2CCC(=O)N1CCOCC1 XVBDWBTYOLKWEW-RXFWQSSRSA-N 0.000 claims description 3
- MAIBSRRVYSUFFI-MHECFPHRSA-N 3-[6-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxynaphthalen-2-yl]-n,n-dimethylprop-2-enamide Chemical compound C([C@@H](O)[C@@H](OC=1C=C2C=CC(C=CC(=O)N(C)C)=CC2=CC=1)C)CC1=CC=CN=C1 MAIBSRRVYSUFFI-MHECFPHRSA-N 0.000 claims description 3
- FUHNNVGGPVIYLB-GAJHUEQPSA-N 3-[6-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxynaphthalen-2-yl]-n-methylpropanamide Chemical compound C([C@@H](O)[C@H](C)OC1=CC2=CC=C(C=C2C=C1)CCC(=O)NC)CC1=CC=CN=C1 FUHNNVGGPVIYLB-GAJHUEQPSA-N 0.000 claims description 3
- HOPWJYYXGWZSSA-HTAPYJJXSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-2-methylbenzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(S(N)(=O)=O)C(C)=C1 HOPWJYYXGWZSSA-HTAPYJJXSA-N 0.000 claims description 3
- NNWBSMDVGAUPCT-MUAVYFROSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-3-methyl-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C(=C1)C)=CC=C1C(=O)NCCN1CCCC1 NNWBSMDVGAUPCT-MUAVYFROSA-N 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 125000006267 biphenyl group Chemical group 0.000 claims description 3
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims description 3
- YLRMJBLFCFRPSK-UPCLLVRISA-N n-[2-fluoro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]acetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(NC(C)=O)C(F)=C1 YLRMJBLFCFRPSK-UPCLLVRISA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 claims description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 3
- IICVQAGLMRNSRC-OYHNWAKOSA-N (3r,4s)-4-[4-(2,4-dichlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1Cl IICVQAGLMRNSRC-OYHNWAKOSA-N 0.000 claims description 2
- PYANXKKQTIRRIV-OYHNWAKOSA-N (3r,4s)-4-[4-(4-chloro-2-fluorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1F PYANXKKQTIRRIV-OYHNWAKOSA-N 0.000 claims description 2
- BSJCKAZKWKRFOS-KSFYIVLOSA-N (3r,4s)-4-[4-(4-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 BSJCKAZKWKRFOS-KSFYIVLOSA-N 0.000 claims description 2
- MPTPZYUYXKUQGZ-GAJHUEQPSA-N (3r,4s)-4-[4-(4-methylsulfonylphenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 MPTPZYUYXKUQGZ-GAJHUEQPSA-N 0.000 claims description 2
- UDULFYHNOLFOJX-UQBPGWFLSA-N (3r,4s)-4-[4-[4-[2-(methylamino)ethyl]phenyl]phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound C1=CC(CCNC)=CC=C1C(C=C1)=CC=C1O[C@@H](C)[C@H](O)CCC1=CC=CN=C1 UDULFYHNOLFOJX-UQBPGWFLSA-N 0.000 claims description 2
- BCEQYHJZIKPULS-KDYSTLNUSA-N (3r,4s)-4-[6-(3-morpholin-4-ylpropyl)naphthalen-2-yl]oxy-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1C=C2)=CC=C1C=C2CCCN1CCOCC1 BCEQYHJZIKPULS-KDYSTLNUSA-N 0.000 claims description 2
- CXZXGBOPQVMNBT-RPWUZVMVSA-N (3r,4s)-5-methyl-4-(4-phenylphenoxy)-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 CXZXGBOPQVMNBT-RPWUZVMVSA-N 0.000 claims description 2
- XXXCMHZVGZNJIO-LHSJRXKWSA-N 2,5-difluoro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC(F)=C(S(N)(=O)=O)C=C1F XXXCMHZVGZNJIO-LHSJRXKWSA-N 0.000 claims description 2
- AYKJNGXQKNZXKS-MHECFPHRSA-N 2-[3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC(C=2C=CC(O[C@@H](C)[C@H](O)CCC=3C=NC=CC=3)=CC=2)=C1 AYKJNGXQKNZXKS-MHECFPHRSA-N 0.000 claims description 2
- YENIBPVGACWEHT-OYHNWAKOSA-N 2-fluoro-5-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C(C(N)=O)=C1 YENIBPVGACWEHT-OYHNWAKOSA-N 0.000 claims description 2
- OWFNIHSSJPPNIQ-RPWUZVMVSA-N 2-fluoro-5-[4-[(3s,4r)-4-hydroxy-6-pyridin-3-ylhexan-3-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](CC)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C(C#N)=C1 OWFNIHSSJPPNIQ-RPWUZVMVSA-N 0.000 claims description 2
- ADWQKTKFOJCPQF-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-n-(2,2,2-trifluoroethyl)benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(=O)(=O)NCC(F)(F)F)=C1 ADWQKTKFOJCPQF-GAJHUEQPSA-N 0.000 claims description 2
- XNOVDHJDGKWEGI-KSFYIVLOSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(N)(=O)=O)=C1 XNOVDHJDGKWEGI-KSFYIVLOSA-N 0.000 claims description 2
- YVPMQWACNWKRIO-KSFYIVLOSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonic acid Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(O)(=O)=O)=C1 YVPMQWACNWKRIO-KSFYIVLOSA-N 0.000 claims description 2
- XNOVDHJDGKWEGI-AOMKIAJQSA-N 3-[4-[(2s,3s)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(N)(=O)=O)=C1 XNOVDHJDGKWEGI-AOMKIAJQSA-N 0.000 claims description 2
- BDBNIPOLEKIRTF-SBUREZEXSA-N 3-[4-[(2s,3s)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(C#N)=C1 BDBNIPOLEKIRTF-SBUREZEXSA-N 0.000 claims description 2
- UABNFGKHVUBOGX-MHECFPHRSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-2-methylbenzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C(C)=C1 UABNFGKHVUBOGX-MHECFPHRSA-N 0.000 claims description 2
- UIRUWVNACMBVTO-KSFYIVLOSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(S(N)(=O)=O)C=C1 UIRUWVNACMBVTO-KSFYIVLOSA-N 0.000 claims description 2
- HNKWJNIRQMOJIP-QMHKHESXSA-N 4-fluoro-3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC(C#N)=CC=C1F HNKWJNIRQMOJIP-QMHKHESXSA-N 0.000 claims description 2
- LUKPEARUSNNSLT-RBISFHTESA-N 5-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-2-(2-morpholin-4-ylethoxy)benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=C1C#N)=CC=C1OCCN1CCOCC1 LUKPEARUSNNSLT-RBISFHTESA-N 0.000 claims description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- LZMATGARSSLFMQ-UHFFFAOYSA-N N-isopropylurea Natural products CC(C)NC(N)=O LZMATGARSSLFMQ-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- DSGWFDHAIIQHTB-AVRWGWEMSA-N n-[4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-3-methylphenyl]acetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(NC(C)=O)C=C1C DSGWFDHAIIQHTB-AVRWGWEMSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- AHXPVBVCQHQQHJ-RBISFHTESA-N (3r,4s)-1-pyridin-3-yl-4-[4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]phenoxy]pentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCCC1 AHXPVBVCQHQQHJ-RBISFHTESA-N 0.000 claims 1
- TZCZHPIFEFVHQO-KSFYIVLOSA-N (3r,4s)-4-[4-(3-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(Cl)=C1 TZCZHPIFEFVHQO-KSFYIVLOSA-N 0.000 claims 1
- FYKUKCDVTOLWER-GAJHUEQPSA-N (3r,4s)-4-[4-(3-methylsulfonylphenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(C)(=O)=O)=C1 FYKUKCDVTOLWER-GAJHUEQPSA-N 0.000 claims 1
- JNEGDDXZRQBNBH-GAJHUEQPSA-N (3r,4s)-4-[4-(4-chloro-2-methoxy-5-methylphenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound COC1=CC(Cl)=C(C)C=C1C(C=C1)=CC=C1O[C@@H](C)[C@H](O)CCC1=CC=CN=C1 JNEGDDXZRQBNBH-GAJHUEQPSA-N 0.000 claims 1
- MDNMOGZYWHIOJP-MHECFPHRSA-N (3r,4s)-4-[4-(5-methoxy-2-methylphenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound COC1=CC=C(C)C(C=2C=CC(O[C@@H](C)[C@H](O)CCC=3C=NC=CC=3)=CC=2)=C1 MDNMOGZYWHIOJP-MHECFPHRSA-N 0.000 claims 1
- YXFVAPZXRHIFCH-MHECFPHRSA-N (3r,4s)-4-[6-[3-(methylamino)propyl]naphthalen-2-yl]oxy-1-pyridin-3-ylpentan-3-ol Chemical compound C([C@@H](O)[C@H](C)OC1=CC2=CC=C(C=C2C=C1)CCCNC)CC1=CC=CN=C1 YXFVAPZXRHIFCH-MHECFPHRSA-N 0.000 claims 1
- ZCXVNJFAOLYGCZ-ZHRRBRCNSA-N (3s,4r)-4-[4-(4-fluorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C=C1 ZCXVNJFAOLYGCZ-ZHRRBRCNSA-N 0.000 claims 1
- TZCZHPIFEFVHQO-AOMKIAJQSA-N (3s,4s)-4-[4-(3-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(Cl)=C1 TZCZHPIFEFVHQO-AOMKIAJQSA-N 0.000 claims 1
- YKFCAHCDMIJARA-MHECFPHRSA-N 2-[2-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC=C1C(C=C1)=CC=C1O[C@@H](C)[C@H](O)CCC1=CC=CN=C1 YKFCAHCDMIJARA-MHECFPHRSA-N 0.000 claims 1
- AKKJOKBESJNYFN-GAJHUEQPSA-N 2-[3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenoxy]acetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(OCC(N)=O)=C1 AKKJOKBESJNYFN-GAJHUEQPSA-N 0.000 claims 1
- IYXFNWQNIOLJPR-KDYSTLNUSA-N 2-[4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-1-pyrrolidin-1-ylethanone Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=C1)=CC=C1CC(=O)N1CCCC1 IYXFNWQNIOLJPR-KDYSTLNUSA-N 0.000 claims 1
- AYWPIUSBFXHTDC-RXFWQSSRSA-N 2-[4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]-n-propan-2-ylacetamide Chemical compound C1=CC(CC(=O)NC(C)C)=CC=C1C(C=C1)=CC=C1O[C@@H](C)[C@H](O)CCC1=CC=CN=C1 AYWPIUSBFXHTDC-RXFWQSSRSA-N 0.000 claims 1
- JPMVIYLNKGWFBU-QMHKHESXSA-N 2-chloro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C(Cl)=C1 JPMVIYLNKGWFBU-QMHKHESXSA-N 0.000 claims 1
- QGBNCJCAZFOHBH-RPWUZVMVSA-N 2-chloro-4-[4-[(3s,4r)-4-hydroxy-6-pyridin-3-ylhexan-3-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](CC)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C(Cl)=C1 QGBNCJCAZFOHBH-RPWUZVMVSA-N 0.000 claims 1
- HHEQAVXKLSNFNE-QMHKHESXSA-N 2-fluoro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C(F)=C1 HHEQAVXKLSNFNE-QMHKHESXSA-N 0.000 claims 1
- FXCIEENRERHDRL-YADHBBJMSA-N 2-fluoro-5-[4-[(3s,4r)-4-hydroxy-6-pyridin-3-ylhexan-3-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](CC)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C(S(N)(=O)=O)=C1 FXCIEENRERHDRL-YADHBBJMSA-N 0.000 claims 1
- LALZMLRSTBMAMJ-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-4-methylbenzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC(S(N)(=O)=O)=CC=C1C LALZMLRSTBMAMJ-GAJHUEQPSA-N 0.000 claims 1
- IMNXBEGFLIWRQY-RBISFHTESA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=1)=CC=CC=1S(=O)(=O)NCCN1CCCC1 IMNXBEGFLIWRQY-RBISFHTESA-N 0.000 claims 1
- ODQDBBCJQPSWPR-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2C=CC(O[C@@H](C)[C@H](O)CCC=3C=NC=CC=3)=CC=2)=C1 ODQDBBCJQPSWPR-GAJHUEQPSA-N 0.000 claims 1
- SCFMWHCNAQAZHW-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(C=2C=CC(O[C@@H](C)[C@H](O)CCC=3C=NC=CC=3)=CC=2)=C1 SCFMWHCNAQAZHW-GAJHUEQPSA-N 0.000 claims 1
- BDBNIPOLEKIRTF-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(C#N)=C1 BDBNIPOLEKIRTF-GAJHUEQPSA-N 0.000 claims 1
- KKLCPJYXDRNFHY-RPBOFIJWSA-N 3-[4-[(3s,4r)-4-hydroxy-2-methyl-6-pyridin-3-ylhexan-3-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(C#N)=C1 KKLCPJYXDRNFHY-RPBOFIJWSA-N 0.000 claims 1
- XNLWJFYYOIRPIO-UHFFFAOYSA-N 3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 XNLWJFYYOIRPIO-UHFFFAOYSA-N 0.000 claims 1
- ZUQDLGOZTLVSTL-HTAPYJJXSA-N 5-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-2-methylbenzenesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C)C(S(N)(=O)=O)=C1 ZUQDLGOZTLVSTL-HTAPYJJXSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- JFXJCYDNTMLKSS-GAJHUEQPSA-N n-[3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]methanesulfonamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(NS(C)(=O)=O)=C1 JFXJCYDNTMLKSS-GAJHUEQPSA-N 0.000 claims 1
- SGOSOAYIQMWJIK-UPCLLVRISA-N n-[3-chloro-4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]acetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(NC(C)=O)C=C1Cl SGOSOAYIQMWJIK-UPCLLVRISA-N 0.000 claims 1
- SWDSMBSBJJYRCQ-AFMDSPMNSA-N n-cyclopropyl-2-[4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]acetamide Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=C1)=CC=C1CC(=O)NC1CC1 SWDSMBSBJJYRCQ-AFMDSPMNSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 abstract description 15
- 230000000172 allergic effect Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 13
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 230000001363 autoimmune Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000002062 proliferating effect Effects 0.000 abstract description 3
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 480
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 443
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 295
- 239000000243 solution Substances 0.000 description 206
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 159
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 138
- 238000005160 1H NMR spectroscopy Methods 0.000 description 136
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 126
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 123
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 123
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 102
- 239000000203 mixture Substances 0.000 description 98
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 93
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 88
- 239000007787 solid Substances 0.000 description 88
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 79
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 79
- 239000003921 oil Substances 0.000 description 78
- 229910000029 sodium carbonate Inorganic materials 0.000 description 69
- 238000004305 normal phase HPLC Methods 0.000 description 66
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 64
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 60
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 54
- 238000010626 work up procedure Methods 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 47
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 40
- 238000001816 cooling Methods 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 239000000284 extract Substances 0.000 description 34
- 239000000706 filtrate Substances 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 33
- 239000000377 silicon dioxide Substances 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 238000004440 column chromatography Methods 0.000 description 32
- VVVJCILWEFJQJH-BLLLJJGKSA-N [4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]boronic acid Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C1=CC=C(B(O)O)C=C1 VVVJCILWEFJQJH-BLLLJJGKSA-N 0.000 description 31
- 238000010438 heat treatment Methods 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000006260 foam Substances 0.000 description 21
- 239000010410 layer Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 15
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 235000006408 oxalic acid Nutrition 0.000 description 10
- 239000012047 saturated solution Substances 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 8
- 150000003891 oxalate salts Chemical class 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 6
- CLRPXACRDTXENY-UHFFFAOYSA-N 3-ethynylpyridine Chemical group C#CC1=CC=CN=C1 CLRPXACRDTXENY-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 6
- YKIFRFWJAYYRLK-UHFFFAOYSA-N 2-(3-bromophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC(Br)=C1 YKIFRFWJAYYRLK-UHFFFAOYSA-N 0.000 description 5
- MUBJNMWVQGHHLG-UHFFFAOYSA-N 3-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(Br)=C1 MUBJNMWVQGHHLG-UHFFFAOYSA-N 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- KYTDZRQMZRBZCM-LAUBAEHRSA-N [4-[(2s,3r)-3-[tert-butyl(dimethyl)silyl]oxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]boronic acid Chemical compound O([C@@H](C)[C@@H](CCC=1C=NC=CC=1)O[Si](C)(C)C(C)(C)C)C1=CC=C(B(O)O)C=C1 KYTDZRQMZRBZCM-LAUBAEHRSA-N 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- VQCJGQMRUJLGMA-ZGTOLYCTSA-N (4r)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)C(O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 VQCJGQMRUJLGMA-ZGTOLYCTSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- DXJHVFIOMSULNE-GAJHUEQPSA-N 2-[4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]acetic acid Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(CC(O)=O)C=C1 DXJHVFIOMSULNE-GAJHUEQPSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- GYCNHFWRPJXTSB-UHFFFAOYSA-N 5-bromo-2-fluorobenzonitrile Chemical compound FC1=CC=C(Br)C=C1C#N GYCNHFWRPJXTSB-UHFFFAOYSA-N 0.000 description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 208000027771 Obstructive airways disease Diseases 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- DIWVBIXQCNRCFE-QMMMGPOBSA-N (2s)-2-methoxy-2-phenylacetic acid Chemical compound CO[C@H](C(O)=O)C1=CC=CC=C1 DIWVBIXQCNRCFE-QMMMGPOBSA-N 0.000 description 3
- KPSBJZBQNQXNLV-SJORKVTESA-N (3r,4s)-4-(4-bromophenoxy)-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](CC)[C@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 KPSBJZBQNQXNLV-SJORKVTESA-N 0.000 description 3
- SMJODYMRQCZLTM-MSOLQXFVSA-N (3r,4s)-4-(4-bromophenoxy)-5-methyl-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 SMJODYMRQCZLTM-MSOLQXFVSA-N 0.000 description 3
- YASBPJQDRUGXLX-UHFFFAOYSA-N 2-(3-bromophenyl)-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CC1=CC=CC(Br)=C1 YASBPJQDRUGXLX-UHFFFAOYSA-N 0.000 description 3
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 3
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 3
- SSONMJWGZLKCAM-UHFFFAOYSA-N 5-bromo-2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(Br)=CC=C1F SSONMJWGZLKCAM-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- QUFRKPIQPZGMIY-FCHUYYIVSA-N [(3r,4s)-4-(4-bromophenoxy)-1-pyridin-3-ylhexan-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound O([C@@H](CC)[C@@H](CCC=1C=NC=CC=1)O[Si](C)(C)C(C)(C)C)C1=CC=C(Br)C=C1 QUFRKPIQPZGMIY-FCHUYYIVSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- LZCLXQDLBQLTDK-SCSAIBSYSA-N ethyl (2R)-lactate Chemical compound CCOC(=O)[C@@H](C)O LZCLXQDLBQLTDK-SCSAIBSYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 3
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- WHWSLNSPPGVJIR-LLVKDONJSA-N (2s)-2-(4-bromophenoxy)-3-methylbutan-1-ol Chemical compound CC(C)[C@@H](CO)OC1=CC=C(Br)C=C1 WHWSLNSPPGVJIR-LLVKDONJSA-N 0.000 description 2
- LKIUVERFTOPQST-VIFPVBQESA-N (2s)-2-(4-bromophenoxy)butan-1-ol Chemical compound CC[C@@H](CO)OC1=CC=C(Br)C=C1 LKIUVERFTOPQST-VIFPVBQESA-N 0.000 description 2
- UJZFDBVYNJRUOF-VIFPVBQESA-N (2s)-2-(4-bromophenoxy)butanal Chemical compound CC[C@@H](C=O)OC1=CC=C(Br)C=C1 UJZFDBVYNJRUOF-VIFPVBQESA-N 0.000 description 2
- DJOHYRITEGTWPF-ZETCQYMHSA-N (2s)-2-(4-bromophenoxy)propan-1-ol Chemical compound OC[C@H](C)OC1=CC=C(Br)C=C1 DJOHYRITEGTWPF-ZETCQYMHSA-N 0.000 description 2
- MWCMUCQKTIZURT-LBPRGKRZSA-N (2s)-2-(4-phenylphenoxy)propan-1-ol Chemical compound C1=CC(O[C@H](CO)C)=CC=C1C1=CC=CC=C1 MWCMUCQKTIZURT-LBPRGKRZSA-N 0.000 description 2
- ZYGBXQQFLBZVRX-VIFPVBQESA-N (2s)-2-(6-bromonaphthalen-2-yl)oxypropan-1-ol Chemical compound C1=C(Br)C=CC2=CC(O[C@H](CO)C)=CC=C21 ZYGBXQQFLBZVRX-VIFPVBQESA-N 0.000 description 2
- XYEXTYDKXANYSL-QGZVFWFLSA-N (2s)-3-methyl-2-(4-phenylphenoxy)butan-1-ol Chemical compound C1=CC(O[C@H](CO)C(C)C)=CC=C1C1=CC=CC=C1 XYEXTYDKXANYSL-QGZVFWFLSA-N 0.000 description 2
- OLKIYJDSLMKNLC-UHFFFAOYSA-N (3-cyano-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(C#N)=C1 OLKIYJDSLMKNLC-UHFFFAOYSA-N 0.000 description 2
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 2
- PKUWQXZBNLXVTL-ZVAWYAOSSA-N (4S)-4-(4-bromophenoxy)-5-methyl-1-pyridin-3-ylhex-1-yn-3-ol Chemical compound O([C@@H](C(C)C)C(O)C#CC=1C=NC=CC=1)C1=CC=C(Br)C=C1 PKUWQXZBNLXVTL-ZVAWYAOSSA-N 0.000 description 2
- IQGVGYRVCRGLBE-ZGTOLYCTSA-N (4r)-4-(4-bromophenoxy)-1-pyridin-3-ylpent-1-yn-3-ol Chemical compound O([C@H](C)C(O)C#CC=1C=NC=CC=1)C1=CC=C(Br)C=C1 IQGVGYRVCRGLBE-ZGTOLYCTSA-N 0.000 description 2
- XZUSIPDBUGNOCM-LBOXEOMUSA-N (4s)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)C(O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-LBOXEOMUSA-N 0.000 description 2
- NADPFZNWCQIJJW-UHFFFAOYSA-N 1,2-dichloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1Cl NADPFZNWCQIJJW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OKUKWIIEAXKUDI-UHFFFAOYSA-N 1-(4-bromophenyl)-3-methylurea Chemical compound CNC(=O)NC1=CC=C(Br)C=C1 OKUKWIIEAXKUDI-UHFFFAOYSA-N 0.000 description 2
- POLQEGVZOWOCIS-UHFFFAOYSA-N 1-phenyl-4-(1-phenylsulfanylcyclopropyl)oxybenzene Chemical group C1CC1(SC=1C=CC=CC=1)OC1=CC=C(C=2C=CC=CC=2)C=C1 POLQEGVZOWOCIS-UHFFFAOYSA-N 0.000 description 2
- GLJWLOQCRSVLGH-UHFFFAOYSA-N 2-(2-bromophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC=C1Br GLJWLOQCRSVLGH-UHFFFAOYSA-N 0.000 description 2
- STBGWLWAHXTFMK-UHFFFAOYSA-N 2-(3-bromophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC(Br)=C1 STBGWLWAHXTFMK-UHFFFAOYSA-N 0.000 description 2
- UQRNXWAMOBWTTH-UHFFFAOYSA-N 2-(3-bromophenyl)-1-morpholin-4-ylethanone Chemical compound BrC1=CC=CC(CC(=O)N2CCOCC2)=C1 UQRNXWAMOBWTTH-UHFFFAOYSA-N 0.000 description 2
- UBHSMTAHDSKWHS-UHFFFAOYSA-N 2-(3-bromophenyl)-n,n-dimethylethanamine;hydrochloride Chemical compound Cl.CN(C)CCC1=CC=CC(Br)=C1 UBHSMTAHDSKWHS-UHFFFAOYSA-N 0.000 description 2
- ZFHNLQQYLVKJBK-UHFFFAOYSA-N 2-(3-bromophenyl)-n-methylethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=CC(Br)=C1 ZFHNLQQYLVKJBK-UHFFFAOYSA-N 0.000 description 2
- CGKOMNPUEGGUPP-UHFFFAOYSA-N 2-(4-bromophenyl)-n-methylethanamine;hydrochloride Chemical compound Cl.CNCCC1=CC=C(Br)C=C1 CGKOMNPUEGGUPP-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 2
- BVYHCQVTVIXTCV-MHECFPHRSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-n,4-dimethylbenzamide Chemical compound CNC(=O)C1=CC=C(C)C(C=2C=CC(O[C@@H](C)[C@H](O)CCC=3C=NC=CC=3)=CC=2)=C1 BVYHCQVTVIXTCV-MHECFPHRSA-N 0.000 description 2
- GRXMMIBZRMKADT-UHFFFAOYSA-N 3-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1Br GRXMMIBZRMKADT-UHFFFAOYSA-N 0.000 description 2
- CFMBNGJNYNLPDL-UHFFFAOYSA-N 3-bromo-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1Br CFMBNGJNYNLPDL-UHFFFAOYSA-N 0.000 description 2
- ZFJOMUKPDWNRFI-UHFFFAOYSA-N 3-bromo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1Br ZFJOMUKPDWNRFI-UHFFFAOYSA-N 0.000 description 2
- IEZYVBACCPVMIS-UHFFFAOYSA-N 3-bromo-n-(2,2,2-trifluoroethyl)benzenesulfonamide Chemical compound FC(F)(F)CNS(=O)(=O)C1=CC=CC(Br)=C1 IEZYVBACCPVMIS-UHFFFAOYSA-N 0.000 description 2
- CGUWEBUQLKJNIC-UHFFFAOYSA-N 3-bromo-n-(2-morpholin-4-ylethyl)benzenesulfonamide;hydrochloride Chemical compound Cl.BrC1=CC=CC(S(=O)(=O)NCCN2CCOCC2)=C1 CGUWEBUQLKJNIC-UHFFFAOYSA-N 0.000 description 2
- DHJFVRUKIKPADK-UHFFFAOYSA-N 3-bromo-n-[2-(dimethylamino)ethyl]benzenesulfonamide;hydrochloride Chemical compound Cl.CN(C)CCNS(=O)(=O)C1=CC=CC(Br)=C1 DHJFVRUKIKPADK-UHFFFAOYSA-N 0.000 description 2
- UVSNSICXRVZAJR-UHFFFAOYSA-N 3-bromo-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(Br)=C1 UVSNSICXRVZAJR-UHFFFAOYSA-N 0.000 description 2
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 2
- MINSVLXUGHJBPH-UHFFFAOYSA-N 4-bromo-2,5-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(F)=C(Br)C=C1F MINSVLXUGHJBPH-UHFFFAOYSA-N 0.000 description 2
- AYQBMZNSJPVADT-UHFFFAOYSA-N 4-bromo-2-chlorobenzonitrile Chemical compound ClC1=CC(Br)=CC=C1C#N AYQBMZNSJPVADT-UHFFFAOYSA-N 0.000 description 2
- BTSVWIADDUQGGP-UHFFFAOYSA-N 4-bromo-2-methylbenzenesulfonamide Chemical compound CC1=CC(Br)=CC=C1S(N)(=O)=O BTSVWIADDUQGGP-UHFFFAOYSA-N 0.000 description 2
- JNMVCQVRHLHGAT-UHFFFAOYSA-N 5-bromo-2-(2-morpholin-4-ylethylamino)benzonitrile Chemical compound N#CC1=CC(Br)=CC=C1NCCN1CCOCC1 JNMVCQVRHLHGAT-UHFFFAOYSA-N 0.000 description 2
- MAGQVUXQRXLNGB-UHFFFAOYSA-N 5-bromo-2-fluorobenzamide Chemical compound NC(=O)C1=CC(Br)=CC=C1F MAGQVUXQRXLNGB-UHFFFAOYSA-N 0.000 description 2
- RXQNKKRGJJRMKD-UHFFFAOYSA-N 5-bromo-2-methylaniline Chemical compound CC1=CC=C(Br)C=C1N RXQNKKRGJJRMKD-UHFFFAOYSA-N 0.000 description 2
- FXNSWDXUWUJLLI-UHFFFAOYSA-N 5-bromo-2-methylbenzenesulfonamide Chemical compound CC1=CC=C(Br)C=C1S(N)(=O)=O FXNSWDXUWUJLLI-UHFFFAOYSA-N 0.000 description 2
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 0 C*Cc1cccnc1 Chemical compound C*Cc1cccnc1 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VFXGSHGDFHQHIE-UHFFFAOYSA-N [4-(4-bromophenoxy)-5-methyl-1-pyridin-3-ylhexan-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound C=1C=CN=CC=1CCC(O[Si](C)(C)C(C)(C)C)C(C(C)C)OC1=CC=C(Br)C=C1 VFXGSHGDFHQHIE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960003280 cupric chloride Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- JVGMRMRSDREMMP-CYBMUJFWSA-N ethyl (2r)-2-(4-phenylphenoxy)propanoate Chemical compound C1=CC(O[C@H](C)C(=O)OCC)=CC=C1C1=CC=CC=C1 JVGMRMRSDREMMP-CYBMUJFWSA-N 0.000 description 2
- BWUWGQJJRDPYQB-QMMMGPOBSA-N ethyl (2s)-2-(4-bromophenoxy)propanoate Chemical compound CCOC(=O)[C@H](C)OC1=CC=C(Br)C=C1 BWUWGQJJRDPYQB-QMMMGPOBSA-N 0.000 description 2
- JVGMRMRSDREMMP-ZDUSSCGKSA-N ethyl (2s)-2-(4-phenylphenoxy)propanoate Chemical compound C1=CC(O[C@@H](C)C(=O)OCC)=CC=C1C1=CC=CC=C1 JVGMRMRSDREMMP-ZDUSSCGKSA-N 0.000 description 2
- UOIHWYXFMQCGRC-JTQLQIEISA-N ethyl (2s)-2-(6-bromonaphthalen-2-yl)oxypropanoate Chemical compound C1=C(Br)C=CC2=CC(O[C@@H](C)C(=O)OCC)=CC=C21 UOIHWYXFMQCGRC-JTQLQIEISA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- ILJWCXPHMFMXOX-NSHDSACASA-N methyl (2S)-2-(4-bromophenoxy)-3-methylbutanoate Chemical compound COC(=O)[C@@H](Oc1ccc(Br)cc1)C(C)C ILJWCXPHMFMXOX-NSHDSACASA-N 0.000 description 2
- BEVSUQKCPNGGOG-JTQLQIEISA-N methyl (2S)-2-(4-bromophenoxy)butanoate Chemical compound CC[C@H](Oc1ccc(Br)cc1)C(=O)OC BEVSUQKCPNGGOG-JTQLQIEISA-N 0.000 description 2
- MMQMBWWSMVQQRU-KRWDZBQOSA-N methyl (2S)-3-methyl-2-(4-phenylphenoxy)butanoate Chemical compound COC(=O)[C@@H](Oc1ccc(cc1)-c1ccccc1)C(C)C MMQMBWWSMVQQRU-KRWDZBQOSA-N 0.000 description 2
- YSGBMDFJWFIEDF-RXMQYKEDSA-N methyl (2r)-2-hydroxy-3-methylbutanoate Chemical compound COC(=O)[C@H](O)C(C)C YSGBMDFJWFIEDF-RXMQYKEDSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- HRBWAJGVVZVRSJ-UHFFFAOYSA-N n-(2-fluoro-4-iodophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(I)C=C1F HRBWAJGVVZVRSJ-UHFFFAOYSA-N 0.000 description 2
- XYSLAPMSALBVOL-UHFFFAOYSA-N n-(3-bromophenyl)-2,2,2-trifluoro-n-methylacetamide Chemical compound FC(F)(F)C(=O)N(C)C1=CC=CC(Br)=C1 XYSLAPMSALBVOL-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 239000012485 toluene extract Substances 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- MWCMUCQKTIZURT-GFCCVEGCSA-N (2r)-2-(4-phenylphenoxy)propan-1-ol Chemical compound C1=CC(O[C@@H](CO)C)=CC=C1C1=CC=CC=C1 MWCMUCQKTIZURT-GFCCVEGCSA-N 0.000 description 1
- MONMFXREYOKQTI-REOHCLBHSA-N (2s)-2-bromopropanoic acid Chemical compound C[C@H](Br)C(O)=O MONMFXREYOKQTI-REOHCLBHSA-N 0.000 description 1
- DHMRSMNEKFDABI-UHFFFAOYSA-N (3-bromophenyl)urea Chemical compound NC(=O)NC1=CC=CC(Br)=C1 DHMRSMNEKFDABI-UHFFFAOYSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- DJFWQIBUAVZYOE-RXFWQSSRSA-N (3r,4s)-1-pyridin-3-yl-4-[4-(3-pyrrolidin-1-ylsulfonylphenyl)phenoxy]pentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C(C=1)=CC=CC=1S(=O)(=O)N1CCCC1 DJFWQIBUAVZYOE-RXFWQSSRSA-N 0.000 description 1
- VQCJGQMRUJLGMA-BLLLJJGKSA-N (3r,4s)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 VQCJGQMRUJLGMA-BLLLJJGKSA-N 0.000 description 1
- NBARALHWLLSEJD-HDPAQNRDSA-N (3r,4s)-4-[4-(3,4-dichlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol;oxalic acid Chemical compound OC(=O)C(O)=O.O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(Cl)C(Cl)=C1 NBARALHWLLSEJD-HDPAQNRDSA-N 0.000 description 1
- ZLMUXCFGLNTBPK-JXVZSMLKSA-N (3r,4s)-4-[4-(3-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol;oxalic acid Chemical compound OC(=O)C(O)=O.O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(Cl)=C1 ZLMUXCFGLNTBPK-JXVZSMLKSA-N 0.000 description 1
- VQCJGQMRUJLGMA-WBMJQRKESA-N (3s,4r)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)[C@@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 VQCJGQMRUJLGMA-WBMJQRKESA-N 0.000 description 1
- VQCJGQMRUJLGMA-LRDDRELGSA-N (3s,4s)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 VQCJGQMRUJLGMA-LRDDRELGSA-N 0.000 description 1
- SMJODYMRQCZLTM-ROUUACIJSA-N (3s,4s)-4-(4-bromophenoxy)-5-methyl-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](C(C)C)[C@@H](O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 SMJODYMRQCZLTM-ROUUACIJSA-N 0.000 description 1
- ZLMUXCFGLNTBPK-VPRHZQQDSA-N (3s,4s)-4-[4-(3-chlorophenyl)phenoxy]-1-pyridin-3-ylpentan-3-ol;oxalic acid Chemical compound OC(=O)C(O)=O.O([C@@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(Cl)=C1 ZLMUXCFGLNTBPK-VPRHZQQDSA-N 0.000 description 1
- PFQUUCXMPUNRLA-UHFFFAOYSA-N (4-bromophenyl)urea Chemical compound NC(=O)NC1=CC=C(Br)C=C1 PFQUUCXMPUNRLA-UHFFFAOYSA-N 0.000 description 1
- LCCMBGOBWALNLT-PLEWWHCXSA-N (4R)-4-(4-phenylphenoxy)-1-pyridin-3-ylpent-1-yn-3-ol Chemical compound O([C@H](C)C(O)C#CC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 LCCMBGOBWALNLT-PLEWWHCXSA-N 0.000 description 1
- SMJODYMRQCZLTM-ZVAWYAOSSA-N (4S)-4-(4-bromophenoxy)-5-methyl-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](C(C)C)C(O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 SMJODYMRQCZLTM-ZVAWYAOSSA-N 0.000 description 1
- LCCMBGOBWALNLT-LBOXEOMUSA-N (4S)-4-(4-phenylphenoxy)-1-pyridin-3-ylpent-1-yn-3-ol Chemical compound O([C@@H](C)C(O)C#CC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 LCCMBGOBWALNLT-LBOXEOMUSA-N 0.000 description 1
- DUYXYYZRKWIAKN-CGAIIQECSA-N (4S)-5-methyl-4-(4-phenylphenoxy)-1-pyridin-3-ylhex-1-yn-3-ol Chemical compound O([C@@H](C(C)C)C(O)C#CC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 DUYXYYZRKWIAKN-CGAIIQECSA-N 0.000 description 1
- XZUSIPDBUGNOCM-PLEWWHCXSA-N (4r)-4-(4-phenylphenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@H](C)C(O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 XZUSIPDBUGNOCM-PLEWWHCXSA-N 0.000 description 1
- ZUYFCHWZCZTSTK-DJNXLDHESA-N (4s)-4-(4-bromophenoxy)-1-pyridin-3-ylhex-1-yn-3-ol Chemical compound O([C@@H](CC)C(O)C#CC=1C=NC=CC=1)C1=CC=C(Br)C=C1 ZUYFCHWZCZTSTK-DJNXLDHESA-N 0.000 description 1
- VQCJGQMRUJLGMA-HKALDPMFSA-N (4s)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-ol Chemical compound O([C@@H](C)C(O)CCC=1C=NC=CC=1)C1=CC=C(Br)C=C1 VQCJGQMRUJLGMA-HKALDPMFSA-N 0.000 description 1
- CXZXGBOPQVMNBT-CGAIIQECSA-N (4s)-5-methyl-4-(4-phenylphenoxy)-1-pyridin-3-ylhexan-3-ol Chemical compound O([C@@H](C(C)C)C(O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 CXZXGBOPQVMNBT-CGAIIQECSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- AFENDNXGAFYKQO-GSVOUGTGSA-N (R)-2-hydroxybutyric acid Chemical compound CC[C@@H](O)C(O)=O AFENDNXGAFYKQO-GSVOUGTGSA-N 0.000 description 1
- CXNZDHBVEUDSQV-UHFFFAOYSA-N 1-[1-(4-phenylphenoxy)cyclopropyl]-3-pyridin-3-ylpropan-1-ol Chemical compound C1CC1(OC=1C=CC(=CC=1)C=1C=CC=CC=1)C(O)CCC1=CC=CN=C1 CXNZDHBVEUDSQV-UHFFFAOYSA-N 0.000 description 1
- ITYCJCVRPBLODP-UHFFFAOYSA-N 1-bromo-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC=C1Br ITYCJCVRPBLODP-UHFFFAOYSA-N 0.000 description 1
- NKYFJZAKUPSUSH-UHFFFAOYSA-N 1-bromo-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(Br)=C1 NKYFJZAKUPSUSH-UHFFFAOYSA-N 0.000 description 1
- XEWYQQVCBDHBQC-UHFFFAOYSA-N 1-bromo-4-chloro-2-methoxy-5-methylbenzene Chemical compound COC1=CC(Cl)=C(C)C=C1Br XEWYQQVCBDHBQC-UHFFFAOYSA-N 0.000 description 1
- BLZNSXFQRKVFRP-UHFFFAOYSA-N 1-bromo-4-methoxy-2-methylbenzene Chemical compound COC1=CC=C(Br)C(C)=C1 BLZNSXFQRKVFRP-UHFFFAOYSA-N 0.000 description 1
- FJLFSYRGFJDJMQ-UHFFFAOYSA-N 1-bromo-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1 FJLFSYRGFJDJMQ-UHFFFAOYSA-N 0.000 description 1
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- DWXSYDKEWORWBT-UHFFFAOYSA-N 2-(2-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-N 0.000 description 1
- JCDMVJNUNZEZNE-UHFFFAOYSA-N 2-(4-bromophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=C(Br)C=C1 JCDMVJNUNZEZNE-UHFFFAOYSA-N 0.000 description 1
- JUSXLWAFYVKNLT-UHFFFAOYSA-N 2-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Br JUSXLWAFYVKNLT-UHFFFAOYSA-N 0.000 description 1
- CUMTUBVTKOYYOU-UHFFFAOYSA-N 2-fluoro-4-iodoaniline Chemical compound NC1=CC=C(I)C=C1F CUMTUBVTKOYYOU-UHFFFAOYSA-N 0.000 description 1
- GROMYTOXVHFGDL-QMHKHESXSA-N 2-fluoro-5-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(F)C(C#N)=C1 GROMYTOXVHFGDL-QMHKHESXSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BDBNIPOLEKIRTF-UZUQRXQVSA-N 3-[4-[(2r,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(C#N)=C1 BDBNIPOLEKIRTF-UZUQRXQVSA-N 0.000 description 1
- BDBNIPOLEKIRTF-HXOBKFHXSA-N 3-[4-[(2r,3s)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzonitrile Chemical compound O([C@H](C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(C#N)=C1 BDBNIPOLEKIRTF-HXOBKFHXSA-N 0.000 description 1
- BPXRZTHFLMDHQW-GAJHUEQPSA-N 3-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1C(C=C1)=CC=C1O[C@@H](C)[C@H](O)CCC1=CC=CN=C1 BPXRZTHFLMDHQW-GAJHUEQPSA-N 0.000 description 1
- HHUDBVMPIHBEER-RPWUZVMVSA-N 3-[4-[(3s,4r)-4-hydroxy-2-methyl-6-pyridin-3-ylhexan-3-yl]oxyphenyl]benzenesulfonamide Chemical compound O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC(S(N)(=O)=O)=C1 HHUDBVMPIHBEER-RPWUZVMVSA-N 0.000 description 1
- JKCYKISVUIVZCS-UHFFFAOYSA-N 3-bromo-4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1Br JKCYKISVUIVZCS-UHFFFAOYSA-N 0.000 description 1
- QHWZMDRKTYTPEE-UHFFFAOYSA-N 3-bromo-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1Br QHWZMDRKTYTPEE-UHFFFAOYSA-N 0.000 description 1
- CHCZAAJOQXWGPQ-UHFFFAOYSA-N 3-bromo-5-(trifluoromethyl)aniline;3-bromo-5-(trifluoromethyl)benzenesulfonamide Chemical compound NC1=CC(Br)=CC(C(F)(F)F)=C1.NS(=O)(=O)C1=CC(Br)=CC(C(F)(F)F)=C1 CHCZAAJOQXWGPQ-UHFFFAOYSA-N 0.000 description 1
- DXILKTXVLIBCCS-UHFFFAOYSA-N 3-bromo-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide;hydrochloride Chemical compound Cl.BrC1=CC=CC(S(=O)(=O)NCCN2CCCC2)=C1 DXILKTXVLIBCCS-UHFFFAOYSA-N 0.000 description 1
- YBNPCJSZMYHDDR-UHFFFAOYSA-N 3-bromo-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(Br)=C1 YBNPCJSZMYHDDR-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- QDWTXRWOKORYQH-UHFFFAOYSA-N 3-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(Br)=C1 QDWTXRWOKORYQH-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- MQGVOSGGRHAKOE-UHFFFAOYSA-N 3-pyridin-3-ylpropanal Chemical compound O=CCCC1=CC=CN=C1 MQGVOSGGRHAKOE-UHFFFAOYSA-N 0.000 description 1
- KBDFTLXSUZBWOW-MHECFPHRSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]-3-methylbenzonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C=C1C KBDFTLXSUZBWOW-MHECFPHRSA-N 0.000 description 1
- YLRTWQXHZYQDGS-BXKMTCNYSA-N 4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]benzene-1,2-dicarbonitrile Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C(C#N)=C1 YLRTWQXHZYQDGS-BXKMTCNYSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
- KZNXALJXBRSMFL-UHFFFAOYSA-N 4-bromo-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Br)C=C1[N+]([O-])=O KZNXALJXBRSMFL-UHFFFAOYSA-N 0.000 description 1
- SBMKFWMFNIEPDN-UHFFFAOYSA-N 4-bromo-2,5-difluorobenzenesulfonyl chloride Chemical compound FC1=CC(S(Cl)(=O)=O)=C(F)C=C1Br SBMKFWMFNIEPDN-UHFFFAOYSA-N 0.000 description 1
- ZCPVDHZKGQQHDS-UHFFFAOYSA-N 4-bromo-2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1F ZCPVDHZKGQQHDS-UHFFFAOYSA-N 0.000 description 1
- HGXWRDPQFZKOLZ-UHFFFAOYSA-N 4-bromo-2-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC=C1C#N HGXWRDPQFZKOLZ-UHFFFAOYSA-N 0.000 description 1
- LPEBMDFRIKYFCF-UHFFFAOYSA-N 4-bromo-2-methylbenzonitrile Chemical compound CC1=CC(Br)=CC=C1C#N LPEBMDFRIKYFCF-UHFFFAOYSA-N 0.000 description 1
- WOJCAJUWLVTIEW-UHFFFAOYSA-N 4-bromo-3-methyl-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(Br)C(C)=CC(C(=O)NCCN2CCCC2)=C1 WOJCAJUWLVTIEW-UHFFFAOYSA-N 0.000 description 1
- KWVXDZLVCISXIB-UHFFFAOYSA-N 4-bromo-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1Br KWVXDZLVCISXIB-UHFFFAOYSA-N 0.000 description 1
- SKXUZFJOLNNWIG-UHFFFAOYSA-N 4-bromo-3-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC=C1Br SKXUZFJOLNNWIG-UHFFFAOYSA-N 0.000 description 1
- STYQHICBPYRHQK-UHFFFAOYSA-N 4-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1 STYQHICBPYRHQK-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- XDTYUYVIGLIFCW-UHFFFAOYSA-N 4-phenylbenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C1=CC=CC=C1 XDTYUYVIGLIFCW-UHFFFAOYSA-N 0.000 description 1
- BPMBNLJJRKCCRT-UHFFFAOYSA-N 4-phenylbenzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC=C1 BPMBNLJJRKCCRT-UHFFFAOYSA-N 0.000 description 1
- VHSFUGXCSGOKJX-UHFFFAOYSA-N 5-oxo-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCC(=O)N1C(=O)OCC1=CC=CC=C1 VHSFUGXCSGOKJX-UHFFFAOYSA-N 0.000 description 1
- YLDFTMJPQJXGSS-UHFFFAOYSA-N 6-bromo-2-naphthol Chemical compound C1=C(Br)C=CC2=CC(O)=CC=C21 YLDFTMJPQJXGSS-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101150018711 AASS gene Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- GQKZBCPTCWJTAS-UHFFFAOYSA-N COCc1ccccc1 Chemical compound COCc1ccccc1 GQKZBCPTCWJTAS-UHFFFAOYSA-N 0.000 description 1
- HZOWYHMPBOHGCL-INIZCTEOSA-N C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c(c(Cl)c1)ccc1Cl Chemical compound C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c(c(Cl)c1)ccc1Cl HZOWYHMPBOHGCL-INIZCTEOSA-N 0.000 description 1
- CGRQUPXKKXBZRP-FQEVSTJZSA-N C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c1cccc(CC(N(C)C)=O)c1 Chemical compound C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c1cccc(CC(N(C)C)=O)c1 CGRQUPXKKXBZRP-FQEVSTJZSA-N 0.000 description 1
- MGQJCRTXIBBNPV-IBGZPJMESA-N C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c1cccc(CC(NC)=O)c1 Chemical compound C[C@@H](CCCc1cnccc1)Oc(cc1)ccc1-c1cccc(CC(NC)=O)c1 MGQJCRTXIBBNPV-IBGZPJMESA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 101100001677 Emericella variicolor andL gene Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PIHJEHYVEFTSGC-UKOKCHKQSA-N OC(=O)C(O)=O.O([C@@H](C(C)C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)C(O)=O.O([C@@H](C(C)C)[C@@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 PIHJEHYVEFTSGC-UKOKCHKQSA-N 0.000 description 1
- PIHJEHYVEFTSGC-ITNPDYSASA-N OC(=O)C(O)=O.O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 Chemical compound OC(=O)C(O)=O.O([C@@H](C(C)C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=CC=C1 PIHJEHYVEFTSGC-ITNPDYSASA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SMYRZEFGJIKIHA-LAUBAEHRSA-N [(3r,4s)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound O([C@@H](C)[C@@H](CCC=1C=NC=CC=1)O[Si](C)(C)C(C)(C)C)C1=CC=C(Br)C=C1 SMYRZEFGJIKIHA-LAUBAEHRSA-N 0.000 description 1
- SMYRZEFGJIKIHA-PBVYKCSPSA-N [(4s)-4-(4-bromophenoxy)-1-pyridin-3-ylpentan-3-yl]oxy-tert-butyl-dimethylsilane Chemical compound O([C@@H](C)C(CCC=1C=NC=CC=1)O[Si](C)(C)C(C)(C)C)C1=CC=C(Br)C=C1 SMYRZEFGJIKIHA-PBVYKCSPSA-N 0.000 description 1
- VJNJWMIMSQRILY-KSFYIVLOSA-N [4-[4-[(2s,3r)-3-hydroxy-5-pyridin-3-ylpentan-2-yl]oxyphenyl]phenyl]urea Chemical compound O([C@@H](C)[C@H](O)CCC=1C=NC=CC=1)C(C=C1)=CC=C1C1=CC=C(NC(N)=O)C=C1 VJNJWMIMSQRILY-KSFYIVLOSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001398 aluminium Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- OWCDMRFUFMERMZ-UHFFFAOYSA-N benzenesulfonamide;hydrochloride Chemical compound Cl.NS(=O)(=O)C1=CC=CC=C1 OWCDMRFUFMERMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- YIBKCPJOFAUAKY-UHFFFAOYSA-N cyclopropylsulfanylbenzene Chemical compound C1CC1SC1=CC=CC=C1 YIBKCPJOFAUAKY-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- LZCLXQDLBQLTDK-BYPYZUCNSA-N ethyl (2S)-lactate Chemical compound CCOC(=O)[C@H](C)O LZCLXQDLBQLTDK-BYPYZUCNSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ZTUJDPKOHPKRMO-UHFFFAOYSA-N hydron;2,2,2-trifluoroethanamine;chloride Chemical compound Cl.NCC(F)(F)F ZTUJDPKOHPKRMO-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GQNMAZUQZDEAFI-UHFFFAOYSA-N lithium;1h-naphthalen-1-ide Chemical compound [Li+].[C-]1=CC=CC2=CC=CC=C21 GQNMAZUQZDEAFI-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- GOZQGZMXFNNSNV-UHFFFAOYSA-N n-(3-bromophenyl)-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC(Br)=C1 GOZQGZMXFNNSNV-UHFFFAOYSA-N 0.000 description 1
- BVADKOYGDKTWMU-UHFFFAOYSA-N n-(4-bromo-3-chlorophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C(Cl)=C1 BVADKOYGDKTWMU-UHFFFAOYSA-N 0.000 description 1
- BYZHUFNLXFFINU-UHFFFAOYSA-N n-(4-bromo-3-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C(C)=C1 BYZHUFNLXFFINU-UHFFFAOYSA-N 0.000 description 1
- SSPBNPXYQLCJTA-UHFFFAOYSA-N n-[2-bromo-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C(F)(F)F)C=C1Br SSPBNPXYQLCJTA-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
- EP-A-0 264 114 and EP-A-0 267 439 disclose certain phenylalkyl- and phenylalkoxypyridine alkanol derivatives and their use as platelet- activating factor (PAF) antagonists.
- PAF platelet- activating factor
- X is O or S
- R 1 and R 2 are independently hydrogen, C ⁇ alkyl or C 3 . 6 cycloalkyl or R 1 and R 2 together with the carbon atom to which they are attached form a C 3 . 6 cycloalkyl group;
- R 3 is hydrogen, and R 4 is C ⁇ _6 alkyl or C 3 . 6 cycloalkyl orR 3 and R 4 together with the carbon atom to which they are attached form a C 3 . 6 cycloalkyl group;
- Ar 1 is indanyl, tetrahydronaphthyl, naphthyl, phenyl, C 7 _ 9 alkylphenyl or biphenyl, which latter four groups can be optionally substituted by one or more groups selected from halo, nitro, cyano, pyridyl, thiazinyl, C ⁇ _ ⁇ o alkyl (optionally substituted by one or more fluorine atoms), -Y-OR 5 , -Y-NR 6 C(O)NR 7 -R 8 , -O-Z-C(O)NR 7 R 8 , -O-Y-C(S)NR 7 R 8 , -Y-C(O)NR 7 R 8 , -Y-
- R 7 and R 8 are independently hydrogen or Q_ 6 alkyl or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulfur;
- R 5 , R 6 , R 9 , R 10 and R 11 are independently hydrogen or -io alkyl (optionally substituted by one or more fluorine atoms);
- Z is Ci. 6 alkylene
- R 12 is a group NR 10 C(O)R U , NR 10 CO 2 R n , OR 5 , NR 7 R 8 or CO 2 R 13 where R 5 , R 7 , R 8 , R 10 and R 11 are as defined above and R 13 is hydrogen, - 6 alkyl, C ⁇ . alkylaryl or aryl optionally substituted by hydroxy, or a salt or solvate thereof.
- Alkyl, alkylene, alkenyl and alkenylene groups, whether alone or part of another group, can be straight chained or branched.
- X is O or S, preferably X is O.
- R 1 and R 2 are independently hydrogen, _ 6 alkyl or C 3 . 6 cycloalkyl or R 1 and R 2 together with the carbon atom to which they are attached form a spiro linked C 3 - 6 cycloalkyl group.
- R 1 and R 2 are both hydrogen.
- R is hydrogen, and R is d_ 6 alkyl or C 3 . 6 cycloalkyl or R and R together with the carbon atom to which they are attached form a C 3 . 6 cycloalkyl group.
- R 3 is hydrogen and R 4 is C ⁇ . 6 alkyl, in particular methyl, ethyl or isopropyl orR 3 and R 4 together with the carbon atom to which they are attached form a cyclopropyl group.
- Ar 1 is indanyl, tetrahydronaphthyl, naphthyl, phenyl, C 7 _ alkylphenyl or biphenyl, which latter four groups can be optionally substituted by one or more groups selected from halo, nitro, cyano, pyridyl, thiazinyl, C ⁇ ;_ ⁇ o alkyl (optionally substituted by one or more fluorine atoms), -Y-OR 5 , -Y-NR 6 C(O)NR 7 -R 8 , -O-Z-C(O)NR 7 R 8 , -O-Y-C(S)NR 7 R 8 , -Y-C(O)NR 7 R 8 , -Y-SO 2 NR 7 R 8 , -Y-NR 7 R 8 , -Y-OC(O)NR 7 R 8 ,
- Ar 1 is a naphthyl or a biphenyl group.
- Preferred sustituents for Ar 1 groups include those groups exemplified herein.
- Ar 1 is biphenyl optionally substituted by one or more substituents selected from halo, cyano, alkyl or SO?NR 7 R 8 . Most preferably Ar 1 is biphenyl substituted by cyano, halo, methyl or -SO 2 NH 2 .
- Particularly preferred compounds of the invention include those exemplified herein in free base form as well as salts or solvates thereof.
- Compounds of the invention can form pharmaceutically acceptable solvates and salts.
- the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, oxalic, mandelic, tartaric and methanesulfonic acids.
- acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, oxalic, mandelic, tartaric and methanesulfonic acids.
- Compounds of the invention may also form alkali metal salts such as magnesium, sodium, potassium and calcium salts.
- Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
- the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
- the invention also extends to any tautomeric forms and mixtures thereof.
- R 1 , R 2 , R 3 , R 4 , X and Ar 1 are as defined in formula (I); or
- R 15 is an Ar 1 substituent as defined in formula (I)
- R 16 is a suitable hydroxy protecting group
- one of R I7 /R 18 is triflate or halo and the other is B(OH) 2 or ZnHal, or and optionally thereafter in any order:
- Reduction of compounds of formula (II) is carried out using conventional procedures, for example by hydrogenation using a palladium catalyst in an inert solvent such as ethyl acetate.
- Reduction of compounds of formula (III) is carried out using conventional procedures, for example using sodium or zinc borohydride or other reducing agents in a suitable solvent such as ethanol.
- Communications 11(7), 513 - 519, 1081) for example at about 100°C in the presence of a suitable catalyst and base (e.g. tetrakis(triphenylphosphine)palladium (0) and aqueous sodium carbonate) in a suitable solvent (e.g. ethanol/toluene).
- a suitable catalyst and base e.g. tetrakis(triphenylphosphine)palladium (0) and aqueous sodium carbonate
- a suitable solvent e.g. ethanol/toluene
- M is lithium, sodium, potassium, MgX' or ZnX' where X' is halogen optionally in the presence of additives such as boron trifluoride.
- Oxidation of a compound of formula (VI) can be carried out under conventional conditions, for example by Swern oxidation.
- R 19 , R 3 and R 4 are as defined in formula (VH1) andL is a leaving group such as halogen or a group which can be activated to subsequently act as a leaving group, for example hydroxy, with a compound of formula (X):
- R 17 is triflate or halogen
- the reaction is carried out under the conditions of the Mitsonobu reaction for example at approximately 0-25°C in the presence of diethyl azodicarboxylate and triphenylphosphine in an appropriate solvent (e.g. toluene).
- an appropriate solvent e.g. toluene
- Compounds of formula (XI) can be prepared by reduction of a compound of formula (XHI) using conventional procedures, for example hydrogenation using a palladium catalyst in an inert solvent such as ethyl acetate, followed by debenzylation using conventional methods such as thos described in 'Protective Groups in Organic Synthesis', 2 nd Edition, T.W. Greene & P.G.M. Wuts, Wiley-Interscience (1991).
- R is as defind above using Heck chemistry.
- compounds of formula (I) where Ar 1 is naphthyl substituted by bromo or iodo can be treated with a palladium catalyst and a compound of formula (XV) in a suitable solvent at elevated temperature. If desired the palladium catalyst can be formed in situ.
- Compounds of formula (I) containing a -Y-C(O)OR 9 group can also be converted to the corresponding carboxylic acids by hydrolysis. Preferred conditions include treatment with lithium hydroxide in a suitable solvent system, for example in water/THF at ambient temperature.
- Compounds of formula (I) containing a -Y-C(O)OH group can also be converted to compounds of formula (I) having a -Y-C(O)NR 7 R 8 group by reacting with the appropriate amine.
- amines of formula HNR 7 R 8 can be reacted in a suitable solvent such as DMF in the presence of 1-hydroxybenzotriazole and l-ethyl-3-(3'- dimethylaminopropyl)-carbodiimide.
- Suitable reducing agents include sodium borohydride or zinc borohydride (Tetrahedron Lett., (1985), 26, 4463).
- triple bond in compounds of formula (XVI) can also be reduced to form compounds of formula (HI) using conventional procedures, for example hydrogenation using a palladium catalyst in an inert solvent such as ethyl acetate.
- Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid.
- Suitable protecting groups for hydroxy include organosilyl groups (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydro- pyranyl.
- Suitable protecting groups for amino include tert-butoxycarbonyl or benzyloxy carbonyl.
- Suitable protecting groups for carboxylic acid include Q_ ⁇ 5 alkyl or benzyl esters. The protection and deprotection of functional groups may take place before or after a reaction step.
- the compounds of the invention are useful because they possess pharmacological activity and -mcrre particularly activity in the modulation of inflammatory and allergic conditions, for example as shown in the test described below.
- the compounds of the invention inhibit the activation of a range of cell types from haematopoetic lineage, including mast cells, neutrophils and eosinophils.
- the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
- the compounds of the invention are indicated for use in the treatment or prevention of allergic, inflammatory, auto-immune, proliferative and hyper-proliferative diseases.
- the compounds of the invention are also indicated in the treatment and prevention of allergic, inflammatory or auto-immune conditions of the lung, including reversible obstructive airways diseases which includes asthma (e.g. bronchial, allergic, intrinsic asthma, extrinsic and chronic asthma), and associated manifestations of the disease (late responses, hyper-responsiveness), also farmer's lung and related diseases, fibrosis, ideopathic interstitial pneumonia, chronic obstructive airways disease (COPD), bronchiectasis, cystic fibrosis, eosinophilic pneumonias, adult respiratory distress syndrome (ARDS), emphysema and alveolitis, for example cryptogenic fibrosing alveolitis.
- asthma e.g. bronchial, allergic, intrinsic asthma, extrinsic and chronic asthma
- associated manifestations of the disease late responses, hyper-responsiveness
- COPD chronic obstructive airways disease
- COPD chronic obstructive airways disease
- ARDS adult
- the compounds of the invention are indicated in the treatment or prevention of allergic, inflammatory or auto-immune conditions in the nose including all conditions characterised by inflammation of the nasal mucous membrane such as acute rhinitis, allergic rhinitis, atrophic rhinitis, chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta and rhinitis sicca, rhinitis medicamentosa, membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis, scrofulous rhinitis, seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis.
- rhinitis and seasonal rhinitis including rhinitis nervosa (hay fever).
- the compounds are also indicated for the treatment of nasal polyps and allergic menifestations of the nasopharynx other than those described hereintofore.
- the compounds of the invention are also indicated the treatment or prevention of allergic, inflammatory or auto-immune conditions of the eye such as conjunctivitis (allergic, acute, vernal, of hay fever, chronic), inflammation disorders of the eyelids, cornea, uveal tract and retina.
- conjunctivitis allergic, acute, vernal, of hay fever, chronic
- inflammation disorders of the eyelids cornea, uveal tract and retina.
- the compounds of the invention are also indicated in the treatment and prevention of allergic, inflammatory and auto-immune conditions of the gastrointestinal tract such as food allergy and food intolerance, ulcerative colitis, Crohn's disease, irritable bowel disease, gastric ulcers, and food related allergic diseases which have symptomatic manifestations remote from the gastrointestinal tract, for example migraine, rhinitis and eczema.
- the compounds of the invention are indicated for use in the treatment or prevention of allergic, inflammatory or auto-immune conditions of the skin such as psoriasis, atopical dermatitis, contact dermatitis/dermatitis herpetiformis, erythema nodosum, urticaria, cutaneous eosinophilias, acne, Alopecia areata, eosinophilic fascitis dermatomyositis, photoallergic sensitivity and periodontal disease.
- allergic, inflammatory or auto-immune conditions of the skin such as psoriasis, atopical dermatitis, contact dermatitis/dermatitis herpetiformis, erythema nodosum, urticaria, cutaneous eosinophilias, acne, Alopecia areata, eosinophilic fascitis dermatomyositis, photoallergic sensitivity and periodontal disease.
- the compounds of the invention are therefore indicated for use in the treatment or prevention of allergic, inflammatory or auto-immune conditions of the joints and connective tissue, including osteoarthritis, rheumatoid arthritis, systemic lupus erythematosis, vasculitis, Wegener's granulomatosis, polyarthritis nodosa, bursitis, tendonitis, gout, Behcet's syndrome, ankylosing sponditis, Reiter's syndrome and psoriatic arthritis.
- the compounds of the invention are indicated in the treatment and prevention of allergic, inflammatory, and auto-immune conditions of the circulatory system including atheroma, reperfusion injury (e.g. on angioplasty), myocardial infarction, thrombosis and vascular and tissue damage caused by ischaemic disease or injury.
- the compounds of the invention are indicated in the treatment and prevention of allergic, inflammatory or auto-immune conditions of the CNS including Parkinson's disease, Alzheimers and other dementias, stroke and subarachnoid haemorrhage.
- the compounds of the invention are indicated in the treatment and prevention of inflammatory conditions of the liver for example hepatitis, cirrhosis and glomerulonephritis.
- the compounds of the invention are indicated in the treatment and prevention of allergic, inflammatory or auto-immune conditions of the bladder and uro-genital tract including cystitis.
- the compounds of the invention are indicated in the treatment and prevention of tumours and other proliferative diseases.
- Administration of the compounds of the invention may be topical (for example by inhalation to the lung).
- the compounds of the invention may be inhaled as a dry powder which may be pressurised or non-pressurised.
- the active ingredient in finely divided form may be used in admixture with a larger sized pharmaceutically acceptable inert carrier.
- the composition may alternatively be pressurised and contain a compressed gas, e.g. nitrogen, or a liquefied gas propellant.
- the active ingredient is preferably finely divided.
- the pressurised composition may also contain a surface active agent.
- the pressurised compositions may be made by conventional methods.
- the compounds of the invention may be administered systemically (for example by oral administration to the gastrointestinal tract).
- the active ingredient may be formulated together with known adjuvants, diluents or carriers using conventional techniques to produce tablets or capsules for oral administration to the gastrointestinal tract.
- Suitable adjuvants, diluents or carriers for oral administration in the form of tablets, capsules and dragees include microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and/or gelatin.
- a pharmaceutical composition including a compound of formula I or a salt or solvate thereof as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- Suitable doses for such oral administration are in the range from 0.3 to 30 mg kg "1 day “1 , for example 3 mg kg "1 day “1 .
- a method of treatment or prophylaxis of a reversible obstructive airways disease, in particular asthma which method comprises administration of a therapeutically effective amount of a compound of formula I as hereinbefore defined, or a pharmaceutically acceptable derivative thereof, to a person suffering from, or susceptible to, the disease.
- Example 1 The invention is illustrated by the following Examples.
- Example 1 The invention is illustrated by the following Examples.
- Example 1 The invention is illustrated by the following Examples.
- Lithium aluminium hydride (86.67 ml, 1.0 M solution in tetrahydrofuran) was added dropwise to a stirred solution of (2R)-2-(biphenyl-4-yloxy)propanoic acid, ethyl ester
- Oxalyl chloride (1.4 ml) was added dropwise to a solution of dimethyl sulfoxide (1.70 ml) in dry dichloromethane (60 ml) at -60°C was dropwise. The resulting solution was stirred for 20 minutes and then a solution of (2R)-2-(biphenyl-4-yloxy)- 1 -propanol (2.88 g,
- Example lb) in dry dichloromethane (20 ml) was added dropwise.
- the mixture was stirred for a further 30 minutes and then triethylamine (11.2 ml) was added dropwise.
- the mixture was allowed to reach room temperature with stirring over 1 hour.
- the mixture was diluted with anhydrous ether (100 ml), filtered and concentrated under reduced pressure.
- the residue was dissolved in dry tetrahydrofuran (20 ml) and added to a solution of l-lithio-2- pyridin-3-ylacetylene [generated by the addition ofn-butyllithium (2.5 M in hexanes, 4.4 ml) to a solution of 3-pyridylacetylene (1.04g) (J. Amer.
- Example 2a Prepared according to the method described in Example lb) from lithium aluminium hydride (41.9 ml, 1.0M solution in ether) and solution (2S)-2-(biphenyl-4-yloxy)propanoic acid, ethyl ester ( 11.3g, Example 2a)) in dry tetrahydrofuran (200 ml) at 0°C.
- the sub-title compound obtained after work-up was used directly without further purification (9.52 g). m.p. 75-78 °C MS (El) 228 (M) +
- Example 4e Prepared according to the method as described in Example 4e) from (3RS,4R)-4-(4- Bromophenoxy)-l-pyridin-3-yl-pentan-3-ol (1.05g, Example 4d), 3-chlorobenzene boronic acid (1.1 g), 2M aqueous sodium carbonate solution (3.6 ml) and
- the diastereomers were separated by normal-phase HPLC eluting with w ⁇ propanol : dichloromethane (1 : 33) to give two oils which were converted to the oxalate salts upon treatment with oxalic acid (excess) in ether to give the title compounds:
- Example 4e Prepared according to the method as described in Example 4e) from (3RS,4R)-4-(4- Bromophenoxy)-l-pyridin-3-yl-pentan-3-ol (l.Og, Example 4d), 4-fluorobenzeneboronic acid (0.62 g), 2M aqueous sodium carbonate solution (2.2 ml) and tetr ⁇ £w(triphenylphosphine)palladium (0) (0.34 g), toluene (30 ml) and ethanol (10 ml) to give the title compound as solid and as a 4: 1 mixture of diastereomers (0.6 g).
- Oxalyl chloride (1.65 ml) was added dropwise to a solution of dimethyl sulfoxide (2.25 ml) in dry dichloromethane (120 ml) at -65°C. The resulting solution was stirred for 10 minutes and then a solution of (2S)-2-(biphenyl-4-yloxy)-3-methylbutan-l-ol (3.40 g, Example 8b)) in dry dichloromethane (30 ml) was added dropwise at -65°C. The mixture was stirred for a further 15 minutes and then triethylamine (12 ml) was added dropwise. The mixture was allowed to warm to 10°C with stirring.
- the diastereomers were separated by normal-phase HPLC eluting with wopropanol : dichloromethane (1 : 20) to give the sub-title compounds as oils which were converted to their oxalic acid salts by treatment with a saturated ethereal solution of oxalic acid.
- Butyllithium (2.5M in hexanes, 6.1 ml) was added to a stirred solution of phenyl- cyclopropylsulfide (2 g) in dry tetrahydrofuran (45 ml) at 0°C, under nitrogen. Stirring was continued for 3 hours at 0°C, the solution was then cooled to -78°C and iodine (4.05 g) in dry tetrahydrofuran (20 ml) added over a 10 minute period. Stirring was continued at this temperature for 15 minutes, then sodium metabisulfite solution (10% aqueous, 20 ml) was added, and the mixture allowed to warm up to room temperature. The iodinated product was extracted into diethyl ether, washed with saturated brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give a light brown oil.
- reaction mixture was concentrated under reduced pressure and the residue purified by column chromatography over silica gel eluting with ethyl acetate : hexane (4 : 1) to give an oil (2.3 g).
- the diastereomers were separated by normal-phase HPLC eluting with ethyl acetate : hexane (4 : 1) to give the sub-title compounds.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 4-chloro-iodobenzene (0.24 g), 2M aqueous sodium carbonate (0.5 ml) and tetr ⁇ f ⁇ s(triphenylphosphine)palladium (0) (0.1 g) in toluene (4 ml) and ethanol (1 ml). The reaction mixture was heated at 100°C for 4 hours. After cooling, the solution was concentrated under reduced pressure.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 4-bromo-3-methylanisole (0.2 g), 2M aqueous sodium carbonate (0.5 ml) and tetr ⁇ fcw(triphenylphosphine)palladium (0) (0.1 g) in toluene (4 ml) and ethanol (1 ml). The reaction mixture was heated at 100°C for 4 hours. After cooling, the solution was concentrated under reduced pressure.
- Example 11 3-bromo-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide hydrochloride (0.385 g, Example 17a)), 2M aqueous sodium carbonate (0.5 ml) and tetraAxs(triphenylphosphine)palladium (0) (0.025 g) in toluene (5 ml) and ethanol (1 ml).
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 3-Bromo-N-methyl-benzenesulfonamide (0.240 g, Example 19a)), 2M aqueous sodium carbonate (0.55 ml) and tetrafcw(triphenylphosphine)palladium (0) (0.020 g) in toluene (5 ml) and ethanol (2 ml). The reaction mixture was heated at 100°C for 4 hours. After cooling, the solution was concentrated under reduced pressure.
- N-(2-Aminoethyl)pyrrolidine (1.61 g) was added dropwise to a solution of 3- bromobenzenesulfonyl chloride (3.61 g) in diethyl ether (100 ml) at room temperature.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 3-bromo-N-(2-pyrrolidin-l-yl-ethyl)benzenesulfonamide hydrochloride (0.355 g, Example 20a)), 2M aqueous sodium carbonate (0.55 ml) and tetra ⁇ w(triphenylphosphine)palladium (0) (0.020 g) in toluene (5 ml) and ethanol (1 ml).
- the reaction mixture was heated at 100°C for 4 hours. After cooling, the solution was concentrated under reduced pressure. Concentrated hydrochloric acid (1 ml) was added to a solution of the residue in methanol (4 ml) and the suspension was stirred at room temperature for 0.75 hours. The mixture was concentrated under reduced pressure and the residue partitioned between diethyl ether and water. The aqueous layer was basified with sodium hydrogen carbonate solution and the aqueous solution was extracted with ethyl acetate. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)- 1 -methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20g, Example 11)), 4-bromo-3-methylbenzonitrile (0.20g), 2M aqueous sodium carbonate solution (0.5 ml) and tetrafc/.s(triphenylphosphine)palladium (0) (0.02 g) in toluene (5 ml) and ethanol (2 ml). The reaction mixture was heated at 100°C under nitrogen for 4 hours. After cooling, the solution was concentrated under reduced pressure.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 4-bromo-3-chloroacetanilide (0.20 g), 2M aqueous sodium carbonate solution (0.5 ml) and tetr ⁇ f ⁇ ' .s(triphenylphosphine)palladium (0) (0.02 g) in toluene (5 ml) and ethanol (2 ml). The reaction mixture was heated at 100°C under nitrogen for 4 hours. After cooling, the solution was concentrated under reduced pressure.
- N,N-Dimethylethylenediamine 1.76 g was added dropwise to a solution of 3- bromobenzenesulfonyl chloride (5.1 lg) in diethyl ether (100 ml) at room temperature. The resulting suspension was stirred for 30 minutes and filtered to afford the sub-title compound as a solid (4.31 g). m.p. 154-156°C
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 3-bromo-N-(2-dimethylamino-ethyl)benzenesulfonamide hydrochloride (0.331 g, Example 23a)), 2M aqueous sodium carbonate (0.723 ml) and tetr ⁇ f ⁇ s(triphenylphosphine)palladium (0) (0.1 g) in toluene (5 ml) and ethanol (2 ml). The reaction was heated at 110°C for 6 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)- 1 -methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 2-(3-bromophenyl)-N-methyl-acetamide (0.244 g, Example 24a)), 2M aqueous sodium carbonate (0.265 ml) and tetrafcw(triphenylphosphine)palladium (0) (0.1 g) in toluene (5 ml) and ethanol (2 ml). The reaction was heated at 110°C for 6 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11), 2-(3-bromophenyl)-N,N-dimethyl-acetamide (0.234 g, Example 25a)), 2M aqueous sodium carbonate (0.241 ml) and tetr ⁇ fcw(triphenylphosphine)palladium (0) (0.1 g) in toluene (5 ml) and ethanol (2 ml). The reaction was heated at 110°C for 6 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.25 g, Example 1 lc)), 4-bromophenylmethylsulfone (0.19 g), 2M aqueous sodium carbonate (0.64 ml) and tetr ⁇ &w(triphenylphosphine)palladium (0) (0.016 g) in ethanol (3 ml) with heating at 90 C for 4 hours. After cooling, the solution was concentrated under reduced pressure. The residue was partitioned between water and ethyl acetate.
- Example 12b Prepared according to the method described in Example 12b) form (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.20 g, Example 11)), 3-bromophenyl-l-morpholin-4-yl-ethanone (0.234 g, Example 28a)), 2M aqueous sodium carbonate (0.241 ml) and tetr ⁇ fa ' .y(triphenylphosphine)palladium (0) (0.1 g) in toluene (5 ml) and ethanol (2 ml). The reaction was heated at 110°C for 6 hours.
- Example 12b Prepared according to the method described in Example 12b) from [2-(4- bromophenyl)ethyl]-N-methylamine hydrochloride (0.214 g, Example 30a)), ethanol (1 ml), toluene (4 ml), 2M aqueous sodium carbonate (0.5 ml), (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)- l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.2 g, Example 11)), and tetraHs(triphenylphosphine)palladium (0) (0.02 g) with heating at 120°C for 4 hours.
- Example 12b Prepared according to the method described in Example 12b) from 3-bromophenylurea (0.215 g), ethanol (1 ml), toluene (4 ml), 2M aqueous sodium carbonate (0.5 ml), (1S,2R)- 4-[2-(tert-butyldimethylsilanyloxy)- 1 -methyl-4-pyridin-3-ylbutoxy enzeneboronic acid (0.2 g, Example 11)), and tetr ⁇ f ⁇ s(triphenylphosphine)palladium (0) (0.02 g) with heating at 120°C for 4 hours.
- Example 12b Prepared according to the method described in Example 12b) from 3,4-dichloro- iodobenzene (0.273 g), ethanol (2 ml), toluene (5 ml), 2M aqueous sodium carbonate (0.5 ml), (lS,2R)-4-[2-(tert-butyldimethylsilanyloxy)-l-methyl-4-pyridin-3- ylbutoxy]benzeneboronic acid (0.2 g, Example 11)), and tetr ⁇ Hy(triphenylphosphine)palladium (0) (0.025 g) with heating at 120°C for 4 hours.
- Example 12b Prepared according to the method described in Example 12b) from 5-bromo-2- fluorophenylsulphonic acid amide (0.191 g, Example 34a)), ethanol (2 ml), toluene (5 ml), 2M aqueous sodium carbonate (0.5 ml), ' (lS,2R)-4-[2-(tert-butyldimethylsilanyloxy)-l- methyl-4-pyridin-3-ylbutoxy]benzeneboronic acid (0.2 g, Example 11)), and tetr ⁇ H ⁇ (triphenylphosphine)palladium (0) (0.025 g) with heating at 80°C for 2 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.20 g, Example 33), 4-bromo-2- chlorobenzonitrile (0.288 g), 2M aqueous sodium carbonate (0.76 ml) and tetr f ⁇ ' ,y(triphenylphosphine)palladium (0) (0.075 g) in ethanol (5 ml) with heating at 90°C for 4 hours.
- Example 41 (IS, 2R)-4'-(2-Hydroxy-l-methyl-4-pyridin-3-yl-butoxy)biphenyl-3-N-suIfonamido- N'-isopropyl-urea.
- Example 40a Prepared according to the method described in Example 40a) from (2S, 3R)-4-(6- bromonaphthalen-2-yloxy)-l-pyridin-3-yl-pentan-3-ol ( 0.60g Example 10), 1-morpholin- 4-yl-propenone ( 1.09g, Example 42a)), palladium acetate (0.03g), tri-o-tolylphosphine (0.09g) and triethylamine (2ml) in acetonitrile (10ml).
- Example 12b Prepared according to the method described in Example 12b) from 3-cyanobenzeneboronic acid (0.40g), (3S,4R)-3-(4-bromo ⁇ henyloxy)-2-methyl-6-(3-pyridyl)hexan-4-ol (0.90g, Example 61d)), 2M aqueous sodium carbonate (2.72 ml) and tetra&w(triphenylphosphine)palladium(0) (0.160 g) in ethanol (4 ml). The reaction mixture was heated at 90°C for 4 hours. After cooling, the solution was poured onto water, and extracted with ethyl acetate. The combined extracts were washed with brine, dried over magnesium sulfate, and filtered.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.190 g, Example 33), l-[2-(4- bromophenoxy)ethyl]pyrrolidine (0.27 g), 2M aqueous sodium carbonate (0.75 ml) and tetr ⁇ Hsftriphenylphosphine)palladium (0) (0.025 g) in ethanol (2 ml). The reaction mixture was heated at 90°C for 4 hours. After cooling, the solution was concentrated under reduced pressure, taken up in ethanol and concentrated again (twice).
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.190 g, Example 33), 5-bromo-2-(2- morpholin-4-yl-ethylamino)benzonitrile (0.31 g, Example 47a)), 2M aqueous sodium carbonate (0.75 ml) and tetrafa ' .s(triphenylphosphine)palladium (0) (0.025 g) in ethanol (2 ml). The reaction mixture was heated at 90°C for 4 hours. After cooling, the solution was concentrated under reduced pressure, taken up in ethanol and concentrated again (twice).
- 3-Bromothioanisole was dissolved in methanol (20 ml) and cooled to 0°C (ice / water bath). A solution of Oxone® (9.22 g) in water (30 ml) was added to this and the resultant cloudy slurry was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and product extracted with dichloromethane. The combined fractions of dichloromethane were washed with brine and dried over anhydrous magnesium sulfate. After filtration, solvent was removed by evaporation under reduced pressure to give the sub-title compound as a solid (1.02 g). m.p.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.2 g, Example 11), l-bromo-3-methanesulfonylbenzene (0.23 g, Example 48a)), ethanol (2 ml), toluene (5 ml), 2M aqueous sodium carbonate (0.5 ml) and tetra/ci, ⁇ (triphenylphosphine)palladium (0) (0.03 g) with heating at reflux temperature 4 hours. After cooling, the solution was concentrated under reduced pressure.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.150 g, Example 33), 3-bromo-2- benzamide (0.20 g), 2M aqueous sodium carbonate (0.50 ml) and tetrafa ' .y(triphenylphosphine)palladium (0) (0.020 g) in ethanol (3 ml) with heating at 90°C for 2 hours. After work up, the residue was purified by normal-phase HPLC eluting with a gradient of 0-25% ethanol in dichloromethane to give the title compound as a solid
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), 5-bromo-2- chloro-4-methoxytoluene (0.12 g), 2M aqueous sodium carbonate (0.57 ml) and tetr ⁇ Hs(triphenylphosphine)palladium (0) (0.014 g) in ethanol (5 ml) with heating at 90°C for 4 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.6 g, Example 33), 4- bromophenylacetic acid (0.624 g), 2M aqueous sodium carbonate (2.5 ml) and tetr ⁇ fa ' .s(triphenylphosphine)palladium (0) (0.5 g) in ethanol (15 ml). The reaction mixture was heated at 100°C for 3 hours. After cooling, the solution was concentrated under reduced pressure. Water was added to the residue then washed with diethyl ether.
- the aqueous layer was acidified with 2M hydrochloric acid and washed with diethyl ether.
- the aqueous layer was neutralised to pH 7.11 and the solid filtered off washing with diethyl ether to give the title compound as a solid (0.431 g).
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), 2-bromo-4- (trifluoromethyl)acetanilide (0.28 g), 2M aqueous sodium carbonate (0.57 ml) and tetr ⁇ w(triphenylphosphine)palladium (0) (0.014 g) in ethanol (5 ml) with heating at reflux for 2 hours.
- Example 12b Prepared according to the method described in Example 12b) from ( lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.150 g, Example 33), 4-bromo-3- methylacetanilide (0.228 g), 2M aqueous sodium carbonate (0.50 ml) and tetr ⁇ fcw(triphenylphosphine)palladium (0) (0.020 g) in ethanol (3 ml) with heating at 90°C for 2 hours.
- Triethylamine (0.6 ml) was added to a stirred solution of 3-bromoaniline (0.5 ml) in dichloromethane (10 ml). The resulting mixture was stirred at room temperature for 15 minutes and then methanesulfonylchloride (0.36 ml) in dichloromethane (5 ml) was added dropwise. The reaction mixture was stirred 3 hours at room temperature. Water was added and the product was extracted with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel eluting with dichloromethane, then methanol to give the sub-title compound as a solid (0.662 g). m.p. 109°C
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.150 g, Example 33), 3- bromomethane sulfonanilide (0.250 g), 2M aqueous sodium carbonate (0.50 ml) and tetraHs(triphenylphosphine)palladium (0) (0.020 g) in ethanol (3 ml) with heating at 90°C for 2 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.30 g, Example 33), 4- bromophenylsulfonic acid amide (0.26 g), ethanol (6 ml), 2M aqueous sodium carbonate (1.0 ml) and tetr ⁇ Hy(triphenylphosphine)palladium (0) (0.03 g) with heating at 90°C for 6 hours.
- Oxalyl chloride (6.0 ml) was added dropwise to a solution of dimethylsulfoxide (7.5 ml) in dry dichloromethane (300 ml) at -70°C. The resulting solution was stirred for 15 minutes and then a solution of (2S)-2-(4-bromophenoxy)-3-methyl- 1 -butanol ( 13 g) in dry dichloromethane (100 ml) was added dropwise at -70°C. The mixture was stirred for a further 15 minutes and then triethylamine (45 ml) was added. The mixture was allowed to warm to 10°C with stirring.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), 4- bromophenylurea (0.16g), 2M aqueous sodium carbonate (0.25 ml) and tetr fcis(triphenylphosphine)palladium (0) (0.1 g) in ethanol (3 ml). The reaction mixture was heated at 100°C for 3 hours. After cooling, the solution was concentrated under reduced pressure. The residue was triturated with acetone and then filtered through silica gel.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), 4-bromo-3- methyl-N-(2-pyrrolidin-l-yl-ethylJbenzamide (0.31 g, Example 63a)), 2M aqueous sodium carbonate (0.57 ml) and tetr fcis(triphenylphosphine)palladium(0) (0.012 g) in ethanol(5 ml) with heating at reflux for 4 hours. After work up, the residue was purified by normal -phase HPLC eluting with a gradient of 0-10% ethanol in dichloromethane to give the title compound as an oil. (0.14 g).
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), (N-2,2,2- trifluoroethyl)-3-bromobenzenesulfonic acid amide (0.25 g, Example 64a)), 2M aqueous sodium carbonate (0.57 ml) and tetr fcis(triphenylphosphine)palladium (0) (0.014 g) in ethanol (5 ml) with heating at 90°C for 2 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.15 g, Example 33), 3-bromo-4- methylphenylsulfonic acid amide (0.25 g, Example 69a)), ethanol (3 ml), 2M aqueous sodium carbonate (0.5 ml) and tetr ⁇ fcis(triphenylphosphine)palladium (0) (0.03 g) with heating at 90°C for 3 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.150 g, Example 33), N-(3-bromo- phenyl)-2,2,2-trifluoro-N-methylacetamide (0.282 g), 2M aqueous sodium carbonate (0.50 ml) and tetr ⁇ £is(triphenylphosphine)palladium (0) (0.020 g) in ethanol (3 ml) with heating at 90°C for 2 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.20 g, Example 33), 3-bromo-5- trifluoromethylbenzosulphonamide (0.40 g, Example 74), 2M aqueous sodium carbonate (0.76 ml) and tetra&is(triphenylphosphine)palladium (0) (0.019 g) in ethanol (5 ml) with heating at 90 °C for 4 hours. After work up, the residue was purified by normal-phase
- Oxalyl chloride (1.45 ml) was added dropwise to a stirred solution of 3-bromo-4- methylbenzoic acid (3.5 g) in dichloromethane (25 ml) and dimethylformamide (1 drop). The mixture was stirred at room temperamre for 2 hours. The solvents were removed under reduced pressure, and the residue dissolved in tetrahydrofuran (10 ml). A portion of this solution (5 ml) was added dropwise to a stirred solution of methylamine in tetrahydrofuran (2M, 10ml), and stirred at room temperature for 3 days. The mixture was poured into water, and the organic phase separated.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-(2-hydroxy- l-methyl-4-pyridin-3-ylbutoxy)benzeneboronic acid (0.2g, Example 33), 5-bromo-2- methylbenzenesulfonic acid amide (1.7g, Example 78a), ethanol (3 ml), 2M aqueous sodium carbonate (0.7 ml) and tetrafcis(triphenylphosphine)palladium (0) (0.03 g) with heating at 80°C for 3 hours. After work-up, the residue was purified by normal-phase
- Example 69a 4-Bromo-2-methylbenzenesulfonic acid amide Prepared by the method of Example 69a) using 3-bromo-4-methylaniline (2.60 g, Example 78a)), sodium nitrite (1.05 g), concentrated hydrochloric acid (20 ml), anhydrous magnesium chloride (2.6 g), acetic acid saturated with sulfur dioxide (50 ml) and copper (II) chloride (0.37 g). The normal work-up and subsequent treatment with ammonium hydroxide (50 ml) followed by the same work-up afforded the subtitle compound as a solid (1.51 g). m.p. 179-180°C MS(APCI) 250/251 (M-H + )
- Example 12b Prepared according to the method described in Example 12b) from 4-[(2S,3R)-5-(pyridin- 3-yl)-3-hydroxypent-2-yloxy]benzeneboronic acid (0.20 g, Example 33), 4-bromo-2- fluorophenylsulfonic acid amide (0.20 g), ethanol (3 ml), 2M aqueous sodium carbonate (1.0 ml) and tetr ⁇ /tis(triphenylphosphine)palladium (0) (0.03 g) with heating at 90°C for 3 hours.
- Example 12b Prepared according to the method described in Example 12b) from (lS,2R)-4-[2-(tert- butyldimethylsilanyloxy)-l-methyl-4-pyridin-3-ylbutoxybenzeneboronic acid (0.200 g, Example 11), 5-bromo-2-fluorobenzamide (0.158g, Example 82a), ethanol (3 ml), 2M aqueous sodium carbonate (0.48ml) and tetr ⁇ &is(tri ⁇ henylphosphine)palladium (0) (0.030 g), heating at 60°C for 8 hours. After cooling, the reaction mixture was evaporated and azeotroped with ethanol.
- Example 10 Prepared according to the method described in Example 40a) from (2S, 3R)-4-(6- bromonaphthalen-2-yloxy)-l-pyridin-3-yl-pentan-3-ol (0.68g Example 10), methyl acrylate (0.76g), palladium acetate (0.04 g), tri-o-tolylphosphine (0.1 1 g) and triethylamine (2 ml) in acetonitrile (10 ml). After work up crude material was purified by flash column chromatography over silica eluting with 20% acetone in isohexane followed by 50% acetone in isohexane to give the sub-title compound as an oil (0.73 g).
- Example 84b 10% palladium on carbon (0.2 g) and ethanol (50 ml). After work up crude material was purified by flash column chromatography over silica eluting with 5% ethanol in dichloromethane to give an oil (0.57 g).
- Trimethyl aluminium (2.9ml, 2.0M solution in toluene) was cautiously added to a suspension of methylamine hydrochloride (0.39g) in toluene (6ml) at 0°C, with stining, under nitrogen. During the addition the temperature of the reaction was kept between 0°C and 5°C. The reaction mixture was then left to come to room temperature for approximately 1 hour.
- This aluminium / amide reagent was added to a solution of (2S,3R)- 3-[6-(3-hydroxy)-5-(pyridin-3-yl)pent-2-yloxy)naphth-2-ylpropanoic acid, methyl ester (0.57g, Example 84b) in toluene (20ml) and heated at reflux temperature, under nitrogen, for 16 hours. After cooling, the reaction mixture was acidified with 2M hydrochloric acid and stirred for 1 hour. The aqueous layer was separated and basified by addition of a saturated solution of sodium bicarbonate then extracted with ethyl acetate (3 x 100ml).
- Example 5b Prepared according to the method as described in Example 5b) from (3R,4S)-3-[4-(4- bromophenoxy)-3-(t-butyldimethylsilanyloxy)hexyl]pyridine (0.71 g, Example88a)), tertbutyl lithium (1.80 ml, 1.7M in hexanes) and tri-isopropylborate (0.74 ml) in dry tetrahydrofuran (25 ml). After work up, the residue was purified by column chromatography eluting with a gradient 0-25% ethanol in ethyl acetate to give the sub-title compound as a foam (0.41 g).
- Example 12b Prepared according to the method described in Example 12b) from from (3R,4S)-3-[4-(4- Bromophenoxy)-3-(t-butyldimethylsilanyloxy)hexyl]pyridine (0.20 g, Example 88b)), 2- fluoro-5-bromophenylsulfonamide (0.177 g, Example 35a)), 2M aqueous sodium carbonate (0.54 ml) and tetr kis(triphenylphosphine)palladium (0) (0.014 g) in ethanol (3 ml) with heating at 90 °C for 4 hours. The residue was purified by column chromatography over silica eluting with ethyl acetate to give the title compound as a foam (0.14 g). MS(APCI) 445(M + H) +
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98911337A EP0971892A1 (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
US09/068,522 US6300352B1 (en) | 1997-03-25 | 1998-03-20 | Pyridine derivatives and pharmaceutical compositions containing them |
SK1305-99A SK130599A3 (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
CA002284200A CA2284200A1 (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
AU65309/98A AU6530998A (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
IL13184698A IL131846A0 (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
EEP199900426A EE9900426A (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
BR9808042-3A BR9808042A (en) | 1997-03-25 | 1998-03-20 | Compound, pharmaceutical composition, and process for preparing compounds. |
KR1019997008714A KR20010005646A (en) | 1997-03-25 | 1998-03-20 | Novel Pyridine Derivatives and Pharmaceutical Compositions Containing Them |
JP54555898A JP2001518115A (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivative and pharmaceutical composition containing the same |
NO994659A NO994659L (en) | 1997-03-25 | 1999-09-24 | New pyridine derivatives and pharmaceutical preparations containing them |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9701100A SE9701100D0 (en) | 1997-03-25 | 1997-03-25 | Novel compounds |
SE9701100-1 | 1997-03-25 | ||
SE9702199-2 | 1997-06-09 | ||
SE9702199A SE9702199D0 (en) | 1997-06-09 | 1997-06-09 | Novel compounds |
SE9704403-6 | 1997-11-28 | ||
SE9704403A SE9704403D0 (en) | 1997-11-28 | 1997-11-28 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042670A1 true WO1998042670A1 (en) | 1998-10-01 |
Family
ID=27355863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1998/000505 WO1998042670A1 (en) | 1997-03-25 | 1998-03-20 | Novel pyridine derivatives and pharmaceutical compositions containing them |
Country Status (17)
Country | Link |
---|---|
US (1) | US6300352B1 (en) |
EP (1) | EP0971892A1 (en) |
JP (1) | JP2001518115A (en) |
KR (1) | KR20010005646A (en) |
CN (1) | CN1257481A (en) |
AR (1) | AR012157A1 (en) |
AU (1) | AU6530998A (en) |
BR (1) | BR9808042A (en) |
CA (1) | CA2284200A1 (en) |
EE (1) | EE9900426A (en) |
ID (1) | ID22660A (en) |
IL (1) | IL131846A0 (en) |
NO (1) | NO994659L (en) |
PL (1) | PL335905A1 (en) |
SK (1) | SK130599A3 (en) |
TR (1) | TR199902350T2 (en) |
WO (1) | WO1998042670A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376524B1 (en) | 2000-06-21 | 2002-04-23 | Sunesis Pharmaceuticals, Inc. | Triphenyl compounds as interleukin-4 antagonists |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
EP1778214A2 (en) * | 2004-07-27 | 2007-05-02 | Smithkline Beecham Corporation | Novel biphenyl compounds and their use |
US10934244B2 (en) | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
CN114989114A (en) * | 2022-06-02 | 2022-09-02 | 杭州福斯特电子材料有限公司 | Synthesis method of N-acryloyl morpholine and photocuring composition |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335779B2 (en) * | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
US7338969B2 (en) * | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
PL376751A1 (en) * | 2002-11-12 | 2006-01-09 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
US7153889B2 (en) * | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
US20040092521A1 (en) * | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
US20070196340A1 (en) * | 2003-05-06 | 2007-08-23 | Aldo Ammendola | Modulation of Pathogenicity |
US7498049B1 (en) * | 2007-01-03 | 2009-03-03 | Shmuel Gonen | Topical treatment of acne with combined herbal extracts and minerals |
LT3921030T (en) * | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264114A1 (en) * | 1986-10-16 | 1988-04-20 | G.D. Searle & Co. | Alpha-[(phenylmethoxy)methyl]pyridine-alkanol derivatives |
EP0267439A2 (en) * | 1986-10-14 | 1988-05-18 | G.D. Searle & Co. | Alpha-(phenylalkyl) pyridinealkanol derivatives |
WO1997020815A1 (en) * | 1995-12-06 | 1997-06-12 | Astra Pharmaceuticals Ltd. | Compounds |
-
1998
- 1998-03-20 KR KR1019997008714A patent/KR20010005646A/en not_active Application Discontinuation
- 1998-03-20 PL PL98335905A patent/PL335905A1/en unknown
- 1998-03-20 WO PCT/SE1998/000505 patent/WO1998042670A1/en not_active Application Discontinuation
- 1998-03-20 CA CA002284200A patent/CA2284200A1/en not_active Abandoned
- 1998-03-20 AU AU65309/98A patent/AU6530998A/en not_active Abandoned
- 1998-03-20 EP EP98911337A patent/EP0971892A1/en not_active Ceased
- 1998-03-20 IL IL13184698A patent/IL131846A0/en unknown
- 1998-03-20 ID IDW991080A patent/ID22660A/en unknown
- 1998-03-20 JP JP54555898A patent/JP2001518115A/en active Pending
- 1998-03-20 BR BR9808042-3A patent/BR9808042A/en not_active IP Right Cessation
- 1998-03-20 EE EEP199900426A patent/EE9900426A/en unknown
- 1998-03-20 CN CN98805262A patent/CN1257481A/en active Pending
- 1998-03-20 SK SK1305-99A patent/SK130599A3/en unknown
- 1998-03-20 TR TR1999/02350T patent/TR199902350T2/en unknown
- 1998-03-20 US US09/068,522 patent/US6300352B1/en not_active Expired - Fee Related
- 1998-03-24 AR ARP980101343A patent/AR012157A1/en unknown
-
1999
- 1999-09-24 NO NO994659A patent/NO994659L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0267439A2 (en) * | 1986-10-14 | 1988-05-18 | G.D. Searle & Co. | Alpha-(phenylalkyl) pyridinealkanol derivatives |
EP0264114A1 (en) * | 1986-10-16 | 1988-04-20 | G.D. Searle & Co. | Alpha-[(phenylmethoxy)methyl]pyridine-alkanol derivatives |
WO1997020815A1 (en) * | 1995-12-06 | 1997-06-12 | Astra Pharmaceuticals Ltd. | Compounds |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6689772B1 (en) | 2000-03-28 | 2004-02-10 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6376524B1 (en) | 2000-06-21 | 2002-04-23 | Sunesis Pharmaceuticals, Inc. | Triphenyl compounds as interleukin-4 antagonists |
EP1778214A2 (en) * | 2004-07-27 | 2007-05-02 | Smithkline Beecham Corporation | Novel biphenyl compounds and their use |
EP1778214A4 (en) * | 2004-07-27 | 2010-04-14 | Glaxosmithkline Llc | Novel biphenyl compounds and their use |
US10934244B2 (en) | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
RU2745065C2 (en) * | 2015-06-15 | 2021-03-18 | ЭнЭмДи ФАРМА A/C | Compounds used for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
CN114989114A (en) * | 2022-06-02 | 2022-09-02 | 杭州福斯特电子材料有限公司 | Synthesis method of N-acryloyl morpholine and photocuring composition |
Also Published As
Publication number | Publication date |
---|---|
US6300352B1 (en) | 2001-10-09 |
NO994659D0 (en) | 1999-09-24 |
CA2284200A1 (en) | 1998-10-01 |
EE9900426A (en) | 2000-04-17 |
EP0971892A1 (en) | 2000-01-19 |
AR012157A1 (en) | 2000-09-27 |
ID22660A (en) | 1999-12-02 |
CN1257481A (en) | 2000-06-21 |
TR199902350T2 (en) | 2000-04-21 |
BR9808042A (en) | 2000-03-08 |
AU6530998A (en) | 1998-10-20 |
JP2001518115A (en) | 2001-10-09 |
IL131846A0 (en) | 2001-03-19 |
SK130599A3 (en) | 2000-05-16 |
PL335905A1 (en) | 2000-05-22 |
KR20010005646A (en) | 2001-01-15 |
NO994659L (en) | 1999-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6300352B1 (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
US5977105A (en) | Compounds | |
JPH02258766A (en) | Substituted 2-pyridone and pyrido-2-thione, preparation thereof, and use thereof in drug | |
US6265409B1 (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
US6143751A (en) | Pyridine derivatives and pharmaceutical compositions containing them | |
MXPA99008489A (en) | Novel pyridine derivatives and pharmaceutical compositions containing them | |
US10597410B2 (en) | Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent | |
AU6236799A (en) | Novel compounds | |
JPH0386882A (en) | Pyrroloquinoline compound | |
CZ343699A3 (en) | Novel pyridine derivatives and pharmaceutical preparations containing thereof | |
EP0460924A1 (en) | Dichloroaniline compound | |
JPH0393773A (en) | Substituted aminopyridines | |
EP0532634A1 (en) | Phthalamic acids and their isomers for treating leukotriene-related diseases | |
WO2000018731A1 (en) | Novel compounds | |
MXPA01002293A (en) | Novel compounds | |
EP1115706A1 (en) | Novel compounds | |
US4714714A (en) | Arachidonic acid analogs | |
AU1872402A (en) | 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131846 Country of ref document: IL Ref document number: 98805262.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09068522 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 65309/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337629 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/008489 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2284200 Country of ref document: CA Ref document number: 2284200 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997008714 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 130599 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 1998 545558 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/02350 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-3436 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998911337 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-3436 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998911337 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997008714 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-3436 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998911337 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998911337 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997008714 Country of ref document: KR |